<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.5.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art550.dtd?><?SourceDTD.Version 5.5.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_GPB294 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><front><journal-meta><journal-id journal-id-type="nlm-ta">Genomics Proteomics Bioinformatics</journal-id><journal-id journal-id-type="iso-abbrev">Genomics Proteomics Bioinformatics</journal-id><journal-title-group><journal-title>Genomics, Proteomics &#x00026; Bioinformatics</journal-title></journal-title-group><issn pub-type="ppub">1672-0229</issn><issn pub-type="epub">2210-3244</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6112337</article-id><article-id pub-id-type="publisher-id">S1672-0229(18)30049-4</article-id><article-id pub-id-type="doi">10.1016/j.gpb.2018.03.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Applications of RNA Indexes for Precision Oncology in Breast Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Liming</given-names></name><xref rid="fn1" ref-type="fn">a</xref></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Zirui</given-names></name><xref rid="fn2" ref-type="fn">b</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Hui</given-names></name><xref rid="fn3" ref-type="fn">c</xref></contrib><contrib contrib-type="author"><name><surname>Qu</surname><given-names>Lianghu</given-names></name><email>lssqlh@mail.sysu.edu.cn</email><xref rid="cor1" ref-type="corresp">&#x0204e;</xref><xref rid="fn4" ref-type="fn">d</xref></contrib></contrib-group><aff id="af005">Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. <email>lssqlh@mail.sysu.edu.cn</email></corresp><fn id="fn1"><label>a</label><p id="np010">ORCID: 0000-0001-9319-5828.</p></fn><fn id="fn2"><label>b</label><p id="np015">ORCID: 0000-0002-1778-488X.</p></fn><fn id="fn3"><label>c</label><p id="np020">ORCID: 0000-0001-9157-3792.</p></fn><fn id="fn4"><label>d</label><p id="np025">ORCID: 0000-0003-3657-2863.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>09</day><month>5</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>4</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>09</day><month>5</month><year>2018</year></pub-date><volume>16</volume><issue>2</issue><fpage>108</fpage><lpage>119</lpage><history><date date-type="received"><day>26</day><month>12</month><year>2017</year></date><date date-type="rev-recd"><day>25</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The Authors</copyright-statement><copyright-year>2018</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="ab005"><p><bold>Precision oncology</bold> aims to offer the most appropriate treatments to cancer patients mainly based on their individual genetic information. Genomics has provided numerous valuable data on driver mutations and risk loci; however, it remains a formidable challenge to transform these data into therapeutic agents. <bold>Transcriptomics</bold> describes the multifarious expression patterns of both mRNAs and non-coding RNAs (ncRNAs), which facilitates the deciphering of genomic codes. In this review, we take <bold>breast cancer</bold> as an example to demonstrate the applications of these rich RNA resources in precision medicine exploration. These include the use of mRNA profiles in triple-negative breast cancer (TNBC) subtyping to inform corresponding candidate targeted therapies; current advancements and achievements of high-throughput <bold>RNA interference</bold> (RNAi) screening technologies in breast cancer; and <bold>microRNAs</bold> as functional signatures for defining cell identities and regulating the biological activities of breast cancer cells. We summarize the benefits of transcriptomic analyses in breast cancer management and propose that unscrambling the core signaling networks of cancer may be an important task of multiple-omic data integration for precision oncology.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Precision oncology</kwd><kwd>Transcriptomics</kwd><kwd>RNA interference</kwd><kwd>microRNA</kwd><kwd>Breast cancer</kwd></kwd-group></article-meta><notes><p id="ms005">Handled by Mofang Liu</p></notes></front><body><sec id="s0005"><title>Introduction</title><p id="p0005">The fundamental mission of precision medicine is to confer the most appropriate management to patients within an appropriate time based on the clinical and molecular characteristics of their diseases <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>. The Precision Medicine Initiative was proposed in 2015, which consists of two main objectives, <italic>i.e.</italic>, a short-term goal aimed to improve cancer management, and a long-term vision promised to provide a better and healthier quality of life <xref rid="b0020" ref-type="bibr">[4]</xref>. Oncology is considered to be &#x0201c;<italic>the clear choice for enhancing the near-term impact of precision medicine</italic>&#x0201d; <xref rid="b0025" ref-type="bibr">[5]</xref>. Recent advancements in sequencing technologies and big data analytics have provided an unprecedented insight into the detailed molecular information of different tumor types, consequently promoting the development of potential targeted therapies and the innovation of clinical-trial strategies <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>. Comprehensive transcriptomic analyses present a global view of the RNA-based variants and contribute to the decoding of genomic data into actual gene expression patterns <xref rid="b0055" ref-type="bibr">[11]</xref>. Transcriptomics is now regarded as an impactful approach to improving the application of genomic information to the identification, confirmation, evaluation and implementation in precision medicine exploration. In this review, we use breast cancer as a model to summarize the groundbreaking advancements and achievements of transcriptomics in cancer management in recent years.</p><p id="p0010">Breast cancer is the most common malignant tumor in women <xref rid="b0060" ref-type="bibr">[12]</xref>. This extremely heterogeneous disease is clinically classified into three types (<xref rid="f0005" ref-type="fig">Figure 1</xref>), mainly depending on the expression status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). The ER<sup>+</sup> group is the most common type of breast cancers (accounting for approximately 70% of all breast cancer cases), and endocrine therapies with selective ER modulators (SERMs) or aromatase inhibitors (AIs) have been adopted as the standard adjuvant treatments for ER<sup>+</sup> tumors <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>. The HER2-overexpressed group has achieved favorable therapeutic effects from the humanized monoclonal antibody trastuzumab that targets HER2 <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>. Triple-negative breast cancer (TNBC) represents a distinctive subset of breast cancers with neither ER/PR expression nor HER2 amplification <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>. TNBC accounts for approximately 15% of all types of breast cancers and is more malignant than the ER<sup>+</sup> or HER2 highly-amplified breast cancers <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>. Current treatment of TNBC largely relies on chemotherapy and radiation therapy, with no targeted drugs approved for TNBC yet.<fig id="f0005"><label>Figure 1</label><caption><p><bold>Schema of the clinical classifications of breast cancers and the corresponding targeted therapies approved</bold></p><p>Breast cancers are clinically classified into three types: ER<sup>+</sup>, HER2<sup>+</sup>, and TNBC, according to the expression status of ER, PR, and HER2, which can be further divided into several subtypes as illustrated. TNBC is associated with the worst prognosis and is more aggressive than the other two types, and currently there are no targeted agents approved for TNBC yet. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; SERM, selective estrogen receptor modulator; AI, aromatase inhibitor; BL, basal-like; IM, immunomodulatory; M, mesenchymal; MSL, mesenchymal stem-like; LAR, luminal androgen receptor; UNS, unstable.</p></caption><graphic xlink:href="gr1"/></fig></p></sec><sec id="s0010"><title>Genomic architecture of breast cancer</title><p id="p0015">The delightful advancements in whole-genome sequencing (WGS) technologies have provided an exhaustive description of the genomic landscape of breast cancer that includes rich information on DNA copy number aberrations (CNAs), driver mutations, and single nucleotide polymorphisms (SNPs) <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref>, <xref rid="b0185" ref-type="bibr">[37]</xref>, <xref rid="b0190" ref-type="bibr">[38]</xref>, <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0200" ref-type="bibr">[40]</xref>, <xref rid="b0205" ref-type="bibr">[41]</xref>, <xref rid="b0210" ref-type="bibr">[42]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0220" ref-type="bibr">[44]</xref>. A large number of CNAs, particularly deletions in <italic>PPP2R2A</italic>, <italic>MTAP</italic>, and <italic>MAP2K4</italic> genes, have been identified in primary breast tumors <xref rid="b0140" ref-type="bibr">[28]</xref>. Using the highly multiplexed single-nucleus sequencing approach, a study involving 1000 single cells from 12 TNBC patients reveals that most CNAs are detected as early as the onset of breast cancer <xref rid="b0175" ref-type="bibr">[35]</xref>. Inactivating mutations of <italic>BRCA1</italic> and <italic>BRCA2</italic> frequently occur in breast cancer as well <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref>, <xref rid="b0210" ref-type="bibr">[42]</xref>, while unique mutations in <italic>GATA3</italic>, <italic>PIK3CA</italic>, and <italic>MAP3K1</italic> are enriched in the luminal A subtype of breast cancer <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0225" ref-type="bibr">[45]</xref>. By analyzing the WGS data from 560 breast cancer samples, Nik-Zainal et al. further find numerous mutations in protein-coding genes <xref rid="b0180" ref-type="bibr">[36]</xref>. TNBC exhibits a higher mutation rate than those observed in ER<sup>+</sup> and HER2<sup>+</sup> breast cancers, particularly in <italic>TP53</italic>, and an enrichment of the <italic>MAGI3</italic>&#x02013;<italic>AKT3</italic> fusion is also detected in TNBC <xref rid="b0120" ref-type="bibr">[24]</xref>. Notably, Ding et al. discover that the metastatic breast cancer shares 20 mutations with the primary tumor <xref rid="b0115" ref-type="bibr">[23]</xref>. Yates et al. further confirm that the majority of mutations detected in the metastatic samples are similar to those present in the primary breast tumors, indicating that the metastatic clones probably arise from the primary tumors <xref rid="b0190" ref-type="bibr">[38]</xref>. Additionally, two <italic>ESR1</italic> mutations (<italic>ESR1<sup>Y537C</sup></italic> and <italic>ESR1<sup>Y537S</sup></italic>) occur after the acquisition of endocrine resistance in response to long-term estrogen deprivation (LTED) <xref rid="b0205" ref-type="bibr">[41]</xref>. In the last decade, genome-wide association studies (GWAS) have also discovered a series of novel breast cancer risk loci <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0235" ref-type="bibr">[47]</xref>, <xref rid="b0240" ref-type="bibr">[48]</xref>, <xref rid="b0245" ref-type="bibr">[49]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>. These GWAS-identified loci contain abundant non-coding SNPs that could alter transcription factor (TF) binding sites and confer breast cancer-specific phenotypic variations <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0255" ref-type="bibr">[51]</xref>. All of these studies have shed light on genetic susceptibilities to breast cancer and facilitated improvements in the prediction and assessment of breast cancer.</p><p id="p0020">Genomic profiling has provided tremendously valuable information on genetic vulnerabilities in breast cancer; however, certain limitations remain. First, DNA variations may not reveal the actual activities of the corresponding biological pathways. In some cases, the master signaling pathways may be deregulated without any observed genomic alterations, and such cases are probably ignored in genomic analyses. Furthermore, even though the genetic variants have been discovered in genomics, it is often difficult to discriminate between &#x0201c;passenger&#x0201d; and &#x0201c;driver&#x0201d; mutations. Functional genomics needs to be replenished by large-scale data derived from other omic platforms. Transcriptomics is the most frequently used method for unscrambling genomic information <xref rid="b0050" ref-type="bibr">[10]</xref>, since it can comprehensively reflect the expression patterns of different kinds of RNAs <xref rid="b0260" ref-type="bibr">[52]</xref>, and is widely applied to investigate the genes that are differentially expressed under specific physiological or pathological conditions <xref rid="b0265" ref-type="bibr">[53]</xref>.</p></sec><sec id="s0015"><title>Novel insights into breast cancer arising from transcriptomic analyses</title><sec id="s0020"><title>Technological advancements in transcriptome profiling</title><p id="p0025">Transcriptomic analyses have been frequently utilized for exploring prospective biomarkers and potential therapeutic targets for human cancers <xref rid="b0265" ref-type="bibr">[53]</xref>. Microarray analysis is useful in measuring the gene expression levels via complementary probe hybridization <xref rid="b0270" ref-type="bibr">[54]</xref>, <xref rid="b0275" ref-type="bibr">[55]</xref>, <xref rid="b0280" ref-type="bibr">[56]</xref> and through which a large number of breast cancer-related genes have been discovered <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0295" ref-type="bibr">[59]</xref>, <xref rid="b0300" ref-type="bibr">[60]</xref>, <xref rid="b0305" ref-type="bibr">[61]</xref>, <xref rid="b0310" ref-type="bibr">[62]</xref>, <xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>, <xref rid="b0325" ref-type="bibr">[65]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>, <xref rid="b0335" ref-type="bibr">[67]</xref>, <xref rid="b0340" ref-type="bibr">[68]</xref>, <xref rid="b0345" ref-type="bibr">[69]</xref>. Furthermore, the wide application of RNA sequencing (RNA-seq) technologies has greatly expanded our knowledge of breast cancer <xref rid="b0135" ref-type="bibr">[27]</xref>. Using RNA-seq, we can quantify genes that are expressed at extremely low levels and hence might be neglected when using microarrays <xref rid="b0350" ref-type="bibr">[70]</xref>, <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0360" ref-type="bibr">[72]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref>, <xref rid="b0370" ref-type="bibr">[74]</xref>. RNA-seq also facilitates the analysis of specific fusion transcripts that are usually enriched in TNBC <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0375" ref-type="bibr">[75]</xref>, <xref rid="b0380" ref-type="bibr">[76]</xref>, <xref rid="b0385" ref-type="bibr">[77]</xref>, <xref rid="b0390" ref-type="bibr">[78]</xref>, <xref rid="b0395" ref-type="bibr">[79]</xref>. More importantly, through manipulating RNA isolation prior to RNA-seq experiments, the transcriptome of specific ncRNA species, <italic>e.g.</italic>, microRNAs (miRNAs), can be enriched for better coverage <xref rid="b0400" ref-type="bibr">[80]</xref>, <xref rid="b0405" ref-type="bibr">[81]</xref>. The applications of the transcriptomics to breast cancer studies are discussed below in more detail.</p></sec><sec id="s0025"><title>Utility of mRNA expression patterns in TNBC subtyping</title><p id="p0030">TNBC is exceedingly heterogeneous, poorly differentiated and highly metastatic <xref rid="b0085" ref-type="bibr">[17]</xref>. It frequently afflicts young women and is associated with poor prognosis. Due to the lack of ER, PR, and HER2 expression, TNBC is insensitive to hormonal therapies. Therefore, conventional cytotoxic chemotherapy and radiation therapy remain the mainstay of treatment for TNBC, whereas the outcomes are far from satisfactory <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0410" ref-type="bibr">[82]</xref>, <xref rid="b0415" ref-type="bibr">[83]</xref>. Efficacious targeted strategies are thus in urgent need for TNBC patients. Revising the sub-classification of TNBC into distinct molecular subtypes with unique transcriptional features is helpful for therapeutic decision-making and prognostic prediction <xref rid="b0410" ref-type="bibr">[82]</xref>, <xref rid="b0415" ref-type="bibr">[83]</xref>, <xref rid="b0420" ref-type="bibr">[84]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0425" ref-type="bibr">[85]</xref>, <xref rid="b0430" ref-type="bibr">[86]</xref>, <xref rid="b0435" ref-type="bibr">[87]</xref>, <xref rid="b0440" ref-type="bibr">[88]</xref>, <xref rid="b0445" ref-type="bibr">[89]</xref>.</p><p id="p0035">Using massively parallel mRNA sequencing, numerous transcripts that are differentially expressed between TNBC and non-TNBC have been identified <xref rid="b0415" ref-type="bibr">[83]</xref>. Based on the comprehensive transcriptomic analysis of 21 breast cancer datasets, Lehmann et al. classify TNBC into seven subtypes <xref rid="b0410" ref-type="bibr">[82]</xref>. These include two basal-like subtypes (BL1 and BL2), an immunomodulatory subtype (IM), a mesenchymal subtype (M), a mesenchymal stem-like subtype (MSL), a luminal androgen receptor subtype (LAR), and an unclassified set that is regarded as unstable (UNS) (<xref rid="f0005" ref-type="fig">Figure 1</xref> and <xref rid="t0005" ref-type="table">Table 1</xref>). The BL1 subtype strongly expresses specific genes that are related to cell proliferation and DNA damage response. It preferentially responds to cisplatin and poly (ADP-ribose) polymerase (PARP) inhibitors. The BL2 subtype is enriched with genes that are associated with growth factor pathways, indicating that growth factor inhibitors may be efficacious for the BL2 subtype. The IM subtype possesses abundant genes that are involved in immune-mediated reactions, and programmed cell death 1/programmed death-ligand 1 (PD1/PDL1) inhibitors are anticipated to be a hopeful therapeutic option for this subtype. Both the M and MSL subtypes specifically express genes that are relevant to cell motility, cellular differentiation, and growth factor pathways, while the MSL subtype expresses lower levels of proliferation genes than those present in the M subtype. The mammalian target of rapamycin (mTOR) inhibitors and epithelial-to-mesenchymal transition (EMT)-targeted agents are candidate drugs for these two subtypes. The LAR subtype is named for the AR enrichment, and anti-androgen treatments (<italic>e.g.</italic>, bicalutamide, an AR antagonist) are undergoing clinical trials <xref rid="b0410" ref-type="bibr">[82]</xref>, <xref rid="b0420" ref-type="bibr">[84]</xref>, <xref rid="b0445" ref-type="bibr">[89]</xref>.<table-wrap id="t0005" position="float"><label>Table 1</label><caption><p><bold>Transcriptomic subtypes of triple-negative breast cancer and potential therapeutic agents</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Subtype</bold></th><th><bold>Percentage (%)</bold></th><th><bold>Cell line models</bold></th><th><bold>Unique pathways</bold></th><th><bold>Potential agents</bold></th></tr></thead><tbody><tr><td>BL1</td><td>17</td><td>HCC2157, HCC1599, HCC1937, HCC1143, HCC3153, HCC38, MDA-MB-468</td><td>Cell cycle<break/>DNA damage response<break/>Proliferation genes</td><td>PARP inhibitors<break/>Cisplatin</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td>BL2</td><td>7</td><td>SUM149PT, CAL-851, HCC70, HCC1806, HDQ-P1</td><td>Cell cycle<break/>DNA damage response<break/>Growth factor signaling</td><td>mTOR inhibitors<break/>Growth factor inhibitors</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td>IM</td><td>18</td><td>HCC1187, DU4475</td><td>Immune signaling<break/>Cytokine signaling<break/>Antigen presentation</td><td>PD1/PDL1 inhibitors</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td>M</td><td>24</td><td>BT-549, CAL-51, CAL-120</td><td>Cell motility<break/>Cell differentiation<break/>Growth factor signaling<break/>EMT</td><td>mTOR inhibitors<break/>EMT-targeted treatment</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td>MSL</td><td>6</td><td>HS578T, MDA-MB-157, SUM159PT, MDA-MB-436, MDA-MB-231</td><td>Cell motility<break/>Cell differentiation<break/>Growth factor signaling<break/>Angiogenesis genes</td><td>PI3K inhibitors<break/>Antiangiogenic therapy<break/>Src antagonist</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td>LAR</td><td>9</td><td>MDA-MB-453, SUM185PE, HCC2185, CAL-148, MFM-223</td><td>Androgen receptor<break/>Luminal gene expression</td><td>Antiandrogen therapy<break/>PI3K/mTOR inhibitors</td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr><tr><td>UNS</td><td>19</td><td>HCC1395, BT20, SW527</td><td>Cell cycle<break/>DNA damage response<break/>Proliferation genes</td><td>PARP inhibitors<break/>Cisplatin</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Note</italic>: Data are obtained from <xref rid="b0410" ref-type="bibr">[82]</xref>. BL, basal-like; IM, immunomodulatory; M, mesenchymal; MSL, mesenchymal stem-like; LAR, luminal androgen receptor; UNS, unstable; PARP, poly(ADP-ribose)polymerase; EMT, epithelial-to-mesenchymal transition; mTOR, mammalian target of rapamycin; PD1, programmed cell death 1; PDL1, programmed death-ligand 1; PI3K, phosphatidylinositide 3-kinase.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s0030"><title>Functional characterization of breast cancer through RNAi screening</title><p id="p0040">Genomic analyses have uncovered a rapidly growing number of genetic variants that may participate in cancer initiation and progression. However, two intractable challenges remain. On one hand, genomic analyses fail to distinguish between the &#x0201c;driver&#x0201d; mutations that are critical for pathogenesis and the &#x0201c;passenger&#x0201d; incidents that occur coincidentally. On the other hand, hundreds of unanticipated synthetic lethal (SL) interactions are hidden in cancerous abnormalities. SL interactions refer to gene pair relationships in which the separate inactivation of either gene does not affect the viability of cancer cells, but joint inactivation is lethal <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0450" ref-type="bibr">[90]</xref>, <xref rid="b0455" ref-type="bibr">[91]</xref>. It is an intelligent approach to authenticating the inactivated genes first and then selectively inhibiting their SL partners to efficaciously kill the specific cancer cells. A well-known example is the use of PARP inhibitors in the management of <italic>BRCA</italic>-mutated breast cancer <xref rid="b0460" ref-type="bibr">[92]</xref>, <xref rid="b0465" ref-type="bibr">[93]</xref>, <xref rid="b0470" ref-type="bibr">[94]</xref>.</p><p id="p0045">To circumvent the aforementioned limitations of genomic studies, loss-of-function RNAi screening technology has been widely adopted to define the functional genes that are necessary for cancer cells and to disclose SL relationships in exploring novel therapeutic options for cancer treatment <xref rid="b0475" ref-type="bibr">[95]</xref>. Two types of RNA tools are used for RNAi, <italic>i.e.</italic>, small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs). siRNAs are applied to achieve transient and short-term gene silencing, whereas vector-based shRNAs enable stable and long-term gene silencing. Both siRNAs and shRNAs can be used in array-based screening or in pooled formats. <xref rid="f0010" ref-type="fig">Figure 2</xref> presents a general flowchart for high-throughput RNAi screening.<fig id="f0010"><label>Figure 2</label><caption><p><bold>A general flowchart for high-throughput RNAi screening</bold></p><p>High-throughput RNAi screening usually comprises three phases. In phase I, the screening strategies, including gene sets, RNAi libraries, and screening scales, are determined mainly depending on the researchers&#x02019; purposes. The results of phenotypic assays are evaluated and normalized for the selection of effective hits. In phase II, the primary hits are validated by a second round of screening to confirm the &#x0201c;driver&#x0201d; genes, uncover the hidden synthetic lethal relationships, and disclose the critical signaling pathways. In phase III, targeted agents are tested both <italic>in vitro</italic> and <italic>in vivo</italic>, alone or in combination with other approved therapies. DE, differentially expressed; siRNA, small interfering RNA; shRNA, short hairpin RNA.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0050">In RNAi screening, a small-scale array can be used to selectively suppress the up-regulated genes that have been detected in previous transcriptomic analyses or the genes that are differentially expressed among different cancer subtypes <xref rid="b0480" ref-type="bibr">[96]</xref>, <xref rid="b0485" ref-type="bibr">[97]</xref>, <xref rid="b0490" ref-type="bibr">[98]</xref>, <xref rid="b0495" ref-type="bibr">[99]</xref>, <xref rid="b0500" ref-type="bibr">[100]</xref>, <xref rid="b0505" ref-type="bibr">[101]</xref>, <xref rid="b0510" ref-type="bibr">[102]</xref>. Bauer et al. have made the first attempt to perform a vector-based shRNA screening targeting 428 genes that are derived from the overlay of a pool of abnormal transcripts in breast cancer and the druggable gene list. They find that inhibiting both <italic>PPMID</italic> and <italic>SP1</italic> significantly reduces the viability of two TNBC cell lines and increases their sensitivity to paclitaxel. When combined with paclitaxel, both CCT007093 and mithramycin, the respective chemical inhibitors of protein phosphatase Mg<sup>2+</sup>/Mn<sup>2+</sup> dependent 1D (PPMID) and specificity protein 1 (SP1), suppress the growth of the paclitaxel-resistant TNBC cells <xref rid="b0480" ref-type="bibr">[96]</xref>. In the same year, Kourtidis et al. have carried out a shRNA screen targeting 150 genes that are co-overexpressed with <italic>HER2</italic> based on previous meta-analyses and discovered that both <italic>NR1D1</italic> and <italic>PBP</italic> are novel survival factors essential for HER2<sup>+</sup> breast cancer cells <xref rid="b0485" ref-type="bibr">[97]</xref>. These two independent studies focus on two different types of breast cancers respectively, and uncover the distinct determinant genes between TNBC and HER2<sup>+</sup> breast cancer. Subsequently, Marotta et al. further expand the number of breast cancer candidate genes and find that the IL-6/JAK2/Stat3 axis is significantly activated in CD44<sup>+</sup>CD24<sup>&#x02212;</sup> breast cancer cells <xref rid="b0495" ref-type="bibr">[99]</xref>. In addition, two other groups perform siRNA screening by selectively focusing on the genes that are enriched in the aberrantly amplified regions in breast cancer, and identify several candidate oncogenic driver genes, such as <italic>RAD21</italic>, <italic>EIF3H</italic>, <italic>CHRAC1</italic>, <italic>TANC2</italic>, and <italic>GNAS</italic>
<xref rid="b0505" ref-type="bibr">[101]</xref>, <xref rid="b0510" ref-type="bibr">[102]</xref>.</p><p id="p0055">The development of large-scale RNAi libraries has enabled non-biased genome-wide loss-of-function screening <xref rid="b0515" ref-type="bibr">[103]</xref>, <xref rid="b0520" ref-type="bibr">[104]</xref>, <xref rid="b0525" ref-type="bibr">[105]</xref>, <xref rid="b0530" ref-type="bibr">[106]</xref>, <xref rid="b0535" ref-type="bibr">[107]</xref>, <xref rid="b0540" ref-type="bibr">[108]</xref>, <xref rid="b0545" ref-type="bibr">[109]</xref>, <xref rid="b0550" ref-type="bibr">[110]</xref>, <xref rid="b0555" ref-type="bibr">[111]</xref>, <xref rid="b0560" ref-type="bibr">[112]</xref>, <xref rid="b0565" ref-type="bibr">[113]</xref>, <xref rid="b0570" ref-type="bibr">[114]</xref>, <xref rid="b0575" ref-type="bibr">[115]</xref>. Using high-throughput siRNA screening targeting the kinome, Brough et al. have defined a set of pharmacologically tractable genes in 34 breast cancer cell lines and uncovered the SL interactions between <italic>PTEN</italic> and <italic>TTK</italic> genes <xref rid="b0515" ref-type="bibr">[103]</xref>. They further investigate the dependencies of kinase genes in ten cancers and utilize the resultant screening data to predict the drug sensitivity of the designated tumor cell lines by integrating with other molecular profiling datasets. They find that both <italic>ERBB3</italic> and <italic>CCND1</italic> are frequently amplified in breast cancer, whereas some skeletal system morphogenesis-related genes, such as <italic>PDGFRA</italic>, <italic>ACVR2B</italic>, <italic>TGFBR2</italic>, <italic>DLG1</italic>, <italic>FGFR1</italic>, and <italic>FGFR2</italic>, are highly-expressed in osteosarcoma <xref rid="b0565" ref-type="bibr">[113]</xref>. In addition, using a pool of siRNAs targeting 17,378 genes, Petrocca et al. confirm that 154 genes are relevant to poor prognosis in breast cancer <xref rid="b0535" ref-type="bibr">[107]</xref>. Marcotte et al. have conducted a genome-wide pooled screening containing 78,432 shRNAs of 16,056 unique genes in 72 cell lines for breast, pancreatic, and ovarian cancer. They discover that 297 genes are generally essential across all the cell lines examined <xref rid="b0520" ref-type="bibr">[104]</xref>. Their further study on 77 breast cancer cell lines reveals that <italic>BRD4</italic> is a putative targeted option for luminal breast cancer and <italic>PIK3CA</italic> mutations probably determine the resistance to bromodomain and extra-terminal domain (BET)-inhibitors <xref rid="b0560" ref-type="bibr">[112]</xref>. Moreover, by performing deep RNAi screening in 398 cancer cell lines, a recent study has identified a wide variety of cancer genes and constructed interaction networks among protein complexes and signaling pathways <xref rid="b0475" ref-type="bibr">[95]</xref>. Taken together, these studies indicate that RNAi screening is a direct and impactful approach to identifying key determinants and informing novel therapeutic agents and drug combination strategies in breast cancer.</p></sec><sec id="s0035"><title>miRNA signatures for TNBC</title><p id="p0060">The majority of human genome, approximately 98%, is transcribed into ncRNAs <xref rid="b0265" ref-type="bibr">[53]</xref>, which consist of housekeeping ncRNAs and regulatory ncRNAs. The former includes rRNA, tRNA, small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), and guide RNA (gRNA), whereas the latter includes miRNA, siRNA, piwi-interacting RNA (piRNA), and long ncRNA (lncRNA) <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0580" ref-type="bibr">[116]</xref>. miRNAs are well known for their involvement in various biological processes <xref rid="b0585" ref-type="bibr">[117]</xref>, <xref rid="b0590" ref-type="bibr">[118]</xref>, and a large number of miRNAs are deregulated in breast cancer <xref rid="b0595" ref-type="bibr">[119]</xref>, <xref rid="b0600" ref-type="bibr">[120]</xref>, <xref rid="b0605" ref-type="bibr">[121]</xref>, <xref rid="b0610" ref-type="bibr">[122]</xref>, <xref rid="b0615" ref-type="bibr">[123]</xref>, <xref rid="b0620" ref-type="bibr">[124]</xref>. Using miRNA profiling in 31 primary TNBC cases and 13 lymph node metastatic samples in comparison with those from 23 matched normal counterparts, Avery-Kiejda et al. have identified 27 miRNAs related to the metastatic capabilities of TNBC cells <xref rid="b0625" ref-type="bibr">[125]</xref>. Additionally, Koduru et al. have compared the publicly available small RNA sequencing data derived from 24 TNBC cases with those from 14 adjacent normal tissue samples and find that 55 aberrantly expressed miRNAs participate in the TGF-&#x003b2; signaling pathway <xref rid="b0630" ref-type="bibr">[126]</xref>.</p><p id="p0065">The expression of some miRNAs is up-regulated in TNBC and these miRNAs may function as tumor promoters to increase the proliferation and/or invasion of TNBC cells. This type of miRNAs is thus termed as oncomiRs, which include miR-146a/146b <xref rid="b0635" ref-type="bibr">[127]</xref>, miR-181a/181b <xref rid="b0640" ref-type="bibr">[128]</xref>, <xref rid="b0645" ref-type="bibr">[129]</xref>, miR-155 <xref rid="b0650" ref-type="bibr">[130]</xref>, <xref rid="b0655" ref-type="bibr">[131]</xref>, miR-21 <xref rid="b0660" ref-type="bibr">[132]</xref>, <xref rid="b0665" ref-type="bibr">[133]</xref>, miR-720 <xref rid="b0670" ref-type="bibr">[134]</xref>, and miR-455 <xref rid="b0675" ref-type="bibr">[135]</xref>. In contrast, the expression of some other miRNAs is decreased in TNBC and may function as tumor suppressors to inhibit cancer cell growth, induce apoptosis, and ameliorate metastasis. These miRNAs are termed as anti-oncomiRs, which include the miR-200 family <xref rid="b0680" ref-type="bibr">[136]</xref>, <xref rid="b0685" ref-type="bibr">[137]</xref>, <xref rid="b0690" ref-type="bibr">[138]</xref>, miR-34a <xref rid="b0695" ref-type="bibr">[139]</xref>, miR-497 <xref rid="b0700" ref-type="bibr">[140]</xref>, miR-1296 <xref rid="b0705" ref-type="bibr">[141]</xref>, miR-223 <xref rid="b0710" ref-type="bibr">[142]</xref>, miR-211 <xref rid="b0715" ref-type="bibr">[143]</xref>, and miR-217 <xref rid="b0720" ref-type="bibr">[144]</xref>. These functional miRNAs and their corresponding targets are shown in <xref rid="f0015" ref-type="fig">Figure 3</xref>. Studies of the systemic delivery of miRNA mimics or inhibitors via nanotechnologies are ongoing and hold great promise for cancer management <xref rid="b0725" ref-type="bibr">[145]</xref>, <xref rid="b0730" ref-type="bibr">[146]</xref>, <xref rid="b0735" ref-type="bibr">[147]</xref>, <xref rid="b0740" ref-type="bibr">[148]</xref>, <xref rid="b0745" ref-type="bibr">[149]</xref>, <xref rid="b0750" ref-type="bibr">[150]</xref>, <xref rid="b0755" ref-type="bibr">[151]</xref>. For example, RNA nanoparticles with an 8-nt sequence that is complementary to the seed region of miR-21 inhibit TNBC tumors in mouse models without affecting other healthy organs <xref rid="b0745" ref-type="bibr">[149]</xref>.<fig id="f0015"><label>Figure 3</label><caption><p><bold>Functional miRNAs involved in TNBC</bold></p><p>Many miRNAs are differentially expressed in TNBC. They may act as tumor promoters (oncomiRs) or tumor suppressors (anti-oncomiRs) to regulate the capacities of proliferation and/or invasion of TNBC by suppressing their corresponding targets. DDR, DNA damage response.</p></caption><graphic xlink:href="gr3"/></fig></p><p id="p0070">According to the critical roles of miRNAs in cell function and fate determination, a &#x0201c;Helm&#x0201d; model has been proposed to describe miRNAs as functional signatures for precisely characterizing cell identities in temporal-spatial specific status that primarily depends on the abundances of different miRNAs and the balance between these miRNAs and their corresponding targets <xref rid="b0760" ref-type="bibr">[152]</xref>. In the case of breast cancer, comprehensive analyses of miRNA profiles combined with the mRNA expression patterns facilitate the illumination of the balance of miRNA-target pairs. We may be able to reclassify the breast cancer subtypes and clarify the unique biological capabilities of the selected cancer cells based on the dominant functional miRNAs.</p></sec></sec><sec id="s0040"><title>Conclusion and perspectives</title><p id="p0075">Transcriptomic analyses have provided massive amounts of information on the gene expression patterns in breast cancer. For clinical applications, the mRNA expression profiles can be employed to classify TNBC into unique molecular subtypes and to propose reliable therapeutic targets. Loss-of-function RNAi screening can be performed to discover the driver mutations and the SL partners of these inactivated genes for exploring novel targeted options. Moreover, an increasing number of miRNA are detected to be differentially expressed in breast cancer, many of which play critical roles as tumor promoters (oncomiRs) or tumor suppressors (anti-oncomiRs). The applications of transcriptomics in breast cancer are summarized in <xref rid="f0020" ref-type="fig">Figure 4</xref>.<fig id="f0020"><label>Figure 4</label><caption><p><bold>Applications of mRNA and miRNA indexes in breast cancer</bold></p><p>Transcriptomic analyses reveal the expression patterns of both mRNAs and miRNAs. TNBC has been classified into different subtypes according to the cluster analysis of the distinct mRNA expression profiles. Additionally, high-throughput RNAi screening is widely applied to authenticate the &#x0201c;driver&#x0201d; inactivated genes and identify the hidden synthetic lethal relationships. Transcriptomic analyses also facilitate the discovery and validation of breast cancer-associated miRNAs. Therapeutic strategies, based on the inhibition and restoration of deregulated miRNAs, are now undergoing trials and hold great promise for breast cancer treatment. ASO, antisense oligonucleotide; LNA, locked nucleic acid; TuD, tough decoy.</p></caption><graphic xlink:href="gr4"/></fig></p><p id="p0080">With the development of high-throughput sequencing technologies and computational analysis tools, it has become much easier to obtain and decipher enormous datasets that are relevant to different biological layers of human cancers besides genomic and transcriptomic studies. Epigenomic studies reveal the architecture of epigenetic alterations in human genes, including DNA methylation and chromatin modifications <xref rid="b0765" ref-type="bibr">[153]</xref>, <xref rid="b0770" ref-type="bibr">[154]</xref>, <xref rid="b0775" ref-type="bibr">[155]</xref>, <xref rid="b0780" ref-type="bibr">[156]</xref>, <xref rid="b0785" ref-type="bibr">[157]</xref>. Proteomic <xref rid="b0790" ref-type="bibr">[158]</xref>, <xref rid="b0795" ref-type="bibr">[159]</xref>, <xref rid="b0800" ref-type="bibr">[160]</xref>, <xref rid="b0805" ref-type="bibr">[161]</xref>, <xref rid="b0810" ref-type="bibr">[162]</xref>, <xref rid="b0815" ref-type="bibr">[163]</xref> and metabolomic <xref rid="b0820" ref-type="bibr">[164]</xref>, <xref rid="b0825" ref-type="bibr">[165]</xref>, <xref rid="b0830" ref-type="bibr">[166]</xref> studies are also useful for elucidating additional faces of cancer biology. Novel strategies for integrating the genomic, transcriptomic, epigenomic, proteomic, and metabolomic data are demanded for a holistic understanding of tumor evolution and development <xref rid="b0835" ref-type="bibr">[167]</xref>, <xref rid="b0840" ref-type="bibr">[168]</xref>, <xref rid="b0845" ref-type="bibr">[169]</xref>, <xref rid="b0850" ref-type="bibr">[170]</xref>, <xref rid="b0855" ref-type="bibr">[171]</xref>. In addition, cancer cells are not isolated entities; rather, they communicate with other stromal cells and adjacent tumor sub-clones. The influence of the tumor microenvironment has come into public notice in recent years <xref rid="b0860" ref-type="bibr">[172]</xref>. It is important and necessary to take the interplay between cancer cells and their microenvironment into account to understand the effects of external stresses on cancer initiation and progression, as illustrated in <xref rid="f0025" ref-type="fig">Figure 5</xref>.<fig id="f0025"><label>Figure 5</label><caption><p><bold>Integration of multi-omic data to converge at the core signaling transduction pathways in cancer management</bold></p><p>Comprehensive analyses of genome, transcriptome, proteome, epigenome, metabolome, and tumor microenvironment delineate the diverse aspects of cancer biology. Integration of these multi-omic data into the core intracellular signaling transduction pathways helps to provide accurate guidelines for cancer diagnosis and treatment.</p></caption><graphic xlink:href="gr5"/></fig></p><p id="p0085">The generation of multi-omic data has become an addictive routine for cancer studies. However, an intractable puzzle arises, that is, it is becoming increasingly intricate to assimilate the rapidly growing number of &#x0201c;big data&#x0201d;, as mentioned by Dr. Weinberg <xref rid="b0865" ref-type="bibr">[173]</xref>, <xref rid="b0870" ref-type="bibr">[174]</xref>, <xref rid="b0875" ref-type="bibr">[175]</xref>, <xref rid="b0880" ref-type="bibr">[176]</xref>. Intelligent utilization and management of these data require massive computational resources and accurate statistical methodologies to unearth the hidden links among different subcomponents <xref rid="b0870" ref-type="bibr">[174]</xref>. Although several data integration algorithms and a panel of software tools have been developed <xref rid="b0885" ref-type="bibr">[177]</xref>, there is still a lack of an impactful paradigm to solve Weinberg&#x02019;s puzzle of how to effectively integrate multifarious information on cancer biology <xref rid="b0865" ref-type="bibr">[173]</xref>. Multi-omic data display the myriad layers of cancer biology in detail, but the endless complexity seems to confuse our vision of the nature and the &#x0201c;Achilles&#x02019; heel&#x0201d; of cancers. Moreover, extreme inter- and intra-tumor heterogeneities originate from the rapid evolution of tumor cells. They may lead to a concept of personalized medicine for cancer therapy, which is based on every individual difference, rather than a concept that tumors are substantially a class of diseases that can be divided into several well-defined categories. We may return to simplicity and attempt to solve the complicated problems by identifying the common master regulators that correspond to the key hallmarks of cancers (<italic>e.g.</italic>, the capabilities of proliferation, metastasis, immune evasion, and energy metabolism) in different malignant cells.</p><p id="p0090">We suppose that the core signaling networks that are derived from hundreds of unique cancer-related signaling transduction pathways may be the appropriate candidates to unravel Weinberg&#x02019;s puzzle. These networks reflect the cell identities, including the varieties of biological capabilities and the temporal&#x02013;spatial status in cell differentiation, and may be used as functional classification criteria for the characterization of different subtypes of human cancers. Accordingly, pathway-targeted drugs and therapeutic strategies may be precisely designed to redress the deregulated networks. The integration of multi-omic data into the core signaling transduction channels that determine the development of cancers may be a potential direction for us to go out from Weinberg&#x02019;s puzzle of the biological &#x0201c;big data&#x0201d; and helps to provide accurate guidelines for diagnosis and management for cancer patients (<xref rid="f0025" ref-type="fig">Figure 5</xref>).</p><p id="p0095">Breast cancer is well-classified using both cellular and molecular features. Titanic efforts have been made to acquire a great deal of multi-omic data that display diverse biological signatures of the development of breast cancer, particularly in TNBC, which has not been well-characterized and for which no targeted drugs are yet available. It is high time for us to take advantage of these rich resources to identify the core signaling networks in TNBC and we are filled with hope that this most difficult-to-treat cancer will be precisely targeted in the near future.</p></sec><sec id="s0045"><title>Competing interests</title><p id="p0100">The authors declare no competing interests.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Marrone</surname><given-names>M.</given-names></name><name><surname>Schilsky</surname><given-names>R.L.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Khoury</surname><given-names>M.J.</given-names></name><name><surname>Freedman</surname><given-names>A.N.</given-names></name></person-group><article-title>Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>24</volume><year>2015</year><fpage>484</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">25750251</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>K.H.</given-names></name><name><surname>Snyder</surname><given-names>M.</given-names></name></person-group><article-title>Omics profiling in precision oncology</article-title><source>Mol Cell Proteomics</source><volume>15</volume><year>2016</year><fpage>2525</fpage><lpage>2536</lpage><pub-id pub-id-type="pmid">27099341</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>S.Q.</given-names></name></person-group><article-title>Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine</article-title><source>Genomics Proteomics Bioinformatics</source><volume>14</volume><year>2016</year><fpage>298</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">27729266</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>F.S.</given-names></name><name><surname>Varmus</surname><given-names>H.</given-names></name></person-group><article-title>A new initiative on precision medicine</article-title><source>N Engl J Med</source><volume>372</volume><year>2015</year><fpage>793</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">25635347</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>D.J.</given-names></name></person-group><article-title>Uncertainty in the era of precision medicine</article-title><source>N Engl J Med</source><volume>375</volume><year>2016</year><fpage>711</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">27557298</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>R.L.</given-names></name><name><surname>Settleman</surname><given-names>J.</given-names></name></person-group><article-title>From cancer genomics to precision oncology&#x02014;tissue's still an issue</article-title><source>Cell</source><volume>157</volume><year>2014</year><fpage>1509</fpage><lpage>1514</lpage><pub-id pub-id-type="pmid">24949964</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Arnedos</surname><given-names>M.</given-names></name><name><surname>Vicier</surname><given-names>C.</given-names></name><name><surname>Loi</surname><given-names>S.</given-names></name><name><surname>Lefebvre</surname><given-names>C.</given-names></name><name><surname>Michiels</surname><given-names>S.</given-names></name><name><surname>Bonnefoi</surname><given-names>H.</given-names></name></person-group><article-title>Precision medicine for metastatic breast cancer&#x02014;limitations and solutions</article-title><source>Nat Rev Clin Oncol</source><volume>12</volume><year>2015</year><fpage>693</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">26196250</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Biankin</surname><given-names>A.V.</given-names></name><name><surname>Piantadosi</surname><given-names>S.</given-names></name><name><surname>Hollingsworth</surname><given-names>S.J.</given-names></name></person-group><article-title>Patient-centric trials for therapeutic development in precision oncology</article-title><source>Nature</source><volume>526</volume><year>2015</year><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">26469047</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Roychowdhury</surname><given-names>S.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name></person-group><article-title>Translating cancer genomes and transcriptomes for precision oncology</article-title><source>CA Cancer J Clin</source><volume>66</volume><year>2016</year><fpage>75</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">26528881</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Senft</surname><given-names>D.</given-names></name><name><surname>Leiserson</surname><given-names>M.D.M.</given-names></name><name><surname>Ruppin</surname><given-names>E.</given-names></name><name><surname>Ronai</surname><given-names>Z.A.</given-names></name></person-group><article-title>Precision oncology: the road ahead</article-title><source>Trends Mol Med</source><volume>23</volume><year>2017</year><fpage>874</fpage><lpage>898</lpage><pub-id pub-id-type="pmid">28887051</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>T.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name></person-group><article-title>Characterizing and annotating the genome using RNA-seq data</article-title><source>Sci China Life Sci</source><volume>60</volume><year>2017</year><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">27294835</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Sestak</surname><given-names>I.</given-names></name><name><surname>Cuzick</surname><given-names>J.</given-names></name></person-group><article-title>Update on breast cancer risk prediction and prevention</article-title><source>Curr Opin Obstet Gynecol</source><volume>27</volume><year>2015</year><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">25517358</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>A.J.</given-names></name><name><surname>Hendrick</surname><given-names>V.M.</given-names></name><name><surname>Williams</surname><given-names>R.</given-names></name><name><surname>Komm</surname><given-names>B.S.</given-names></name></person-group><article-title>Selective estrogen receptor modulators in clinical practice: a safety overview</article-title><source>Expert Opin Drug Saf</source><volume>14</volume><year>2015</year><fpage>921</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">25936229</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Lumachi</surname><given-names>F.</given-names></name><name><surname>Santeufemia</surname><given-names>D.A.</given-names></name><name><surname>Basso</surname><given-names>S.M.</given-names></name></person-group><article-title>Current medical treatment of estrogen receptor-positive breast cancer</article-title><source>World J Biol Chem</source><volume>6</volume><year>2015</year><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">26322178</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Gradishar</surname><given-names>W.J.</given-names></name></person-group><article-title>HER2 therapy &#x02014; an abundance of riches</article-title><source>N Engl J Med</source><volume>366</volume><year>2012</year><fpage>176</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">22149874</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Figueroa-Magalh&#x000e3;es</surname><given-names>M.C.</given-names></name><name><surname>Jelovac</surname><given-names>D.</given-names></name><name><surname>Connolly</surname><given-names>R.</given-names></name><name><surname>Wolff</surname><given-names>A.C.</given-names></name></person-group><article-title>Treatment of HER2-positive breast cancer</article-title><source>Breast</source><volume>23</volume><year>2014</year><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">24360619</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Foulkes</surname><given-names>W.D.</given-names></name><name><surname>Smith</surname><given-names>I.E.</given-names></name><name><surname>Reis-Filho</surname><given-names>J.S.</given-names></name></person-group><article-title>Triple-negative breast cancer</article-title><source>N Engl J Med</source><volume>363</volume><year>2010</year><fpage>1938</fpage><lpage>1948</lpage><pub-id pub-id-type="pmid">21067385</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Hurvitz</surname><given-names>S.</given-names></name><name><surname>Mead</surname><given-names>M.</given-names></name></person-group><article-title>Triple-negative breast cancer: advancements in characterization and treatment approach</article-title><source>Curr Opin Obstet Gynecol</source><volume>28</volume><year>2016</year><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">26694831</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>B.D.</given-names></name><name><surname>Pietenpol</surname><given-names>J.A.</given-names></name></person-group><article-title>Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes</article-title><source>J Pathol</source><volume>232</volume><year>2014</year><fpage>142</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">24114677</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Hirshfield</surname><given-names>K.M.</given-names></name><name><surname>Ganesan</surname><given-names>S.</given-names></name></person-group><article-title>Triple-negative breast cancer: molecular subtypes and targeted therapy</article-title><source>Curr Opin Obstet Gynecol</source><volume>26</volume><year>2014</year><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">24346128</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Judes</surname><given-names>G.</given-names></name><name><surname>Rifa&#x000ef;</surname><given-names>K.</given-names></name><name><surname>Daures</surname><given-names>M.</given-names></name><name><surname>Dubois</surname><given-names>L.</given-names></name><name><surname>Bignon</surname><given-names>Y.J.</given-names></name><name><surname>Penault-Llorca</surname><given-names>F.</given-names></name></person-group><article-title>High-throughput &#x000ab;Omics&#x000bb; technologies: new tools for the study of triple-negative breast cancer</article-title><source>Cancer Lett</source><volume>382</volume><year>2016</year><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">26965997</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>L.Y.</given-names></name><name><surname>Shanmugam</surname><given-names>M.K.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name><name><surname>Bishayee</surname><given-names>A.</given-names></name></person-group><article-title>Potential role of targeted therapies in the treatment of triple-negative breast cancer</article-title><source>Anticancer Drugs</source><volume>27</volume><year>2016</year><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">26682525</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L.</given-names></name><name><surname>Ellis</surname><given-names>M.J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Larson</surname><given-names>D.E.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Wallis</surname><given-names>J.W.</given-names></name></person-group><article-title>Genome remodelling in a basal-like breast cancer metastasis and xenograft</article-title><source>Nature</source><volume>464</volume><year>2010</year><fpage>999</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">20393555</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Banerji</surname><given-names>S.</given-names></name><name><surname>Cibulskis</surname><given-names>K.</given-names></name><name><surname>Rangel-Escareno</surname><given-names>C.</given-names></name><name><surname>Brown</surname><given-names>K.K.</given-names></name><name><surname>Carter</surname><given-names>S.L.</given-names></name><name><surname>Frederick</surname><given-names>A.M.</given-names></name></person-group><article-title>Sequence analysis of mutations and translocations across breast cancer subtypes</article-title><source>Nature</source><volume>486</volume><year>2012</year><fpage>405</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">22722202</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>The Cancer Genome Atlas Network</surname></name></person-group><article-title>Comprehensive molecular portraits of human breast tumours</article-title><source>Nature</source><volume>490</volume><year>2012</year><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">23000897</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Popova</surname><given-names>T.</given-names></name><name><surname>Mani&#x000e9;</surname><given-names>E.</given-names></name><name><surname>Rieunier</surname><given-names>G.</given-names></name><name><surname>Caux-Moncoutier</surname><given-names>V.</given-names></name><name><surname>Tirapo</surname><given-names>C.</given-names></name><name><surname>Dubois</surname><given-names>T.</given-names></name></person-group><article-title>Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with <italic>BRCA1/2</italic> inactivation</article-title><source>Cancer Res</source><volume>72</volume><year>2012</year><fpage>5454</fpage><lpage>5462</lpage><pub-id pub-id-type="pmid">22933060</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>S.P.</given-names></name><name><surname>Roth</surname><given-names>A.</given-names></name><name><surname>Goya</surname><given-names>R.</given-names></name><name><surname>Oloumi</surname><given-names>A.</given-names></name><name><surname>Ha</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>The clonal and mutational evolution spectrum of primary triple-negative breast cancers</article-title><source>Nature</source><volume>486</volume><year>2012</year><fpage>395</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">22495314</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>C.</given-names></name><name><surname>Shah</surname><given-names>S.P.</given-names></name><name><surname>Chin</surname><given-names>S.F.</given-names></name><name><surname>Turashvili</surname><given-names>G.</given-names></name><name><surname>Rueda</surname><given-names>O.M.</given-names></name><name><surname>Dunning</surname><given-names>M.J.</given-names></name></person-group><article-title>The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</article-title><source>Nature</source><volume>486</volume><year>2012</year><fpage>346</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">22522925</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Michailidou</surname><given-names>K.</given-names></name><name><surname>Hall</surname><given-names>P.</given-names></name><name><surname>Gonzalez-Neira</surname><given-names>A.</given-names></name><name><surname>Ghoussaini</surname><given-names>M.</given-names></name><name><surname>Dennis</surname><given-names>J.</given-names></name><name><surname>Milne</surname><given-names>R.L.</given-names></name></person-group><article-title>Large-scale genotyping identifies 41 new loci associated with breast cancer risk</article-title><source>Nat Genet</source><volume>45</volume><year>2013</year><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">23535729</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>L.B.</given-names></name><name><surname>Nik-Zainal</surname><given-names>S.</given-names></name><name><surname>Wedge</surname><given-names>D.C.</given-names></name><name><surname>Aparicio</surname><given-names>S.A.</given-names></name><name><surname>Behjati</surname><given-names>S.</given-names></name><name><surname>Biankin</surname><given-names>A.V.</given-names></name></person-group><article-title>Signatures of mutational processes in human cancer</article-title><source>Nature</source><volume>500</volume><year>2013</year><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">23945592</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.C.</given-names></name><name><surname>Alvarez</surname><given-names>M.J.</given-names></name><name><surname>Talos</surname><given-names>F.</given-names></name><name><surname>Dhruv</surname><given-names>H.</given-names></name><name><surname>Rieckhof</surname><given-names>G.E.</given-names></name><name><surname>Iyer</surname><given-names>A.</given-names></name></person-group><article-title>Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks</article-title><source>Cell</source><volume>159</volume><year>2014</year><fpage>402</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">25303533</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Foedermayr</surname><given-names>M.</given-names></name><name><surname>Sebesta</surname><given-names>M.</given-names></name><name><surname>Rudas</surname><given-names>M.</given-names></name><name><surname>Berghoff</surname><given-names>A.S.</given-names></name><name><surname>Promberger</surname><given-names>R.</given-names></name><name><surname>Preusser</surname><given-names>M.</given-names></name></person-group><article-title><italic>BRCA-1</italic> methylation and <italic>TP53</italic> mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy</article-title><source>Cancer Chemother Pharmacol</source><volume>73</volume><year>2014</year><fpage>771</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">24526178</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>M.D.</given-names></name><name><surname>Tsimelzon</surname><given-names>A.</given-names></name><name><surname>Poage</surname><given-names>G.M.</given-names></name><name><surname>Covington</surname><given-names>K.R.</given-names></name><name><surname>Contreras</surname><given-names>A.</given-names></name><name><surname>Fuqua</surname><given-names>S.A.</given-names></name></person-group><article-title>Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer</article-title><source>Clin Cancer Res</source><volume>21</volume><year>2015</year><fpage>1688</fpage><lpage>1698</lpage><pub-id pub-id-type="pmid">25208879</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Michailidou</surname><given-names>K.</given-names></name><name><surname>Beesley</surname><given-names>J.</given-names></name><name><surname>Lindstrom</surname><given-names>S.</given-names></name><name><surname>Canisius</surname><given-names>S.</given-names></name><name><surname>Dennis</surname><given-names>J.</given-names></name><name><surname>Lush</surname><given-names>M.J.</given-names></name></person-group><article-title>Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer</article-title><source>Nat Genet</source><volume>47</volume><year>2015</year><fpage>373</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">25751625</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R.</given-names></name><name><surname>Davis</surname><given-names>A.</given-names></name><name><surname>McDonald</surname><given-names>T.O.</given-names></name><name><surname>Sei</surname><given-names>E.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Punctuated copy number evolution and clonal stasis in triple-negative breast cancer</article-title><source>Nat Genet</source><volume>48</volume><year>2016</year><fpage>1119</fpage><lpage>1130</lpage><pub-id pub-id-type="pmid">27526321</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname><given-names>S.</given-names></name><name><surname>Davies</surname><given-names>H.</given-names></name><name><surname>Staaf</surname><given-names>J.</given-names></name><name><surname>Ramakrishna</surname><given-names>M.</given-names></name><name><surname>Glodzik</surname><given-names>D.</given-names></name><name><surname>Zou</surname><given-names>X.</given-names></name></person-group><article-title>Landscape of somatic mutations in 560 breast cancer whole-genome sequences</article-title><source>Nature</source><volume>534</volume><year>2016</year><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">27135926</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>B.</given-names></name><name><surname>Chin</surname><given-names>S.F.</given-names></name><name><surname>Rueda</surname><given-names>O.M.</given-names></name><name><surname>Vollan</surname><given-names>H.K.</given-names></name><name><surname>Provenzano</surname><given-names>E.</given-names></name><name><surname>Bardwell</surname><given-names>H.A.</given-names></name></person-group><article-title>The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes</article-title><source>Nature Commun</source><volume>7</volume><year>2016</year><fpage>11479</fpage><pub-id pub-id-type="pmid">27161491</pub-id></element-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>L.R.</given-names></name><name><surname>Knappskog</surname><given-names>S.</given-names></name><name><surname>Wedge</surname><given-names>D.</given-names></name><name><surname>Farmery</surname><given-names>J.H.R.</given-names></name><name><surname>Gonzalez</surname><given-names>S.</given-names></name><name><surname>Martincorena</surname><given-names>I.</given-names></name></person-group><article-title>Genomic evolution of breast cancer metastasis and relapse</article-title><source>Cancer Cell</source><volume>32</volume><year>2017</year><fpage>169</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">28810143</pub-id></element-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Michailidou</surname><given-names>K.</given-names></name><name><surname>Lindstr&#x000f6;m</surname><given-names>S.</given-names></name><name><surname>Dennis</surname><given-names>J.</given-names></name><name><surname>Beesley</surname><given-names>J.</given-names></name><name><surname>Hui</surname><given-names>S.</given-names></name><name><surname>Kar</surname><given-names>S.</given-names></name></person-group><article-title>Association analysis identifies 65 new breast cancer risk loci</article-title><source>Nature</source><volume>551</volume><year>2017</year><fpage>92</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">29059683</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Zehir</surname><given-names>A.</given-names></name><name><surname>Benayed</surname><given-names>R.</given-names></name><name><surname>Shah</surname><given-names>R.H.</given-names></name><name><surname>Syed</surname><given-names>A.</given-names></name><name><surname>Middha</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>H.R.</given-names></name></person-group><article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title><source>Nat Med</source><volume>23</volume><year>2017</year><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">28481359</pub-id></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>L.A.</given-names></name><name><surname>Ribas</surname><given-names>R.</given-names></name><name><surname>Simigdala</surname><given-names>N.</given-names></name><name><surname>Schuster</surname><given-names>E.</given-names></name><name><surname>Pancholi</surname><given-names>S.</given-names></name><name><surname>Tenev</surname><given-names>T.</given-names></name></person-group><article-title>Discovery of naturally occurring <italic>ESR1</italic> mutations in breast cancer cell lines modelling endocrine resistance</article-title><source>Nat Commun</source><volume>8</volume><year>2017</year><fpage>1865</fpage><pub-id pub-id-type="pmid">29192207</pub-id></element-citation></ref><ref id="b0210"><label>42</label><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name><surname>Polak</surname><given-names>P.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Braunstein</surname><given-names>L.Z.</given-names></name><name><surname>Karlic</surname><given-names>R.</given-names></name><name><surname>Haradhavala</surname><given-names>N.J.</given-names></name><name><surname>Tiao</surname><given-names>G.</given-names></name></person-group><article-title>A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer</article-title><source>Nat Genet</source><volume>49</volume><year>2017</year><fpage>1476</fpage><lpage>1486</lpage><pub-id pub-id-type="pmid">28825726</pub-id></element-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name><surname>Rheinbay</surname><given-names>E.</given-names></name><name><surname>Parasuraman</surname><given-names>P.</given-names></name><name><surname>Grimsby</surname><given-names>J.</given-names></name><name><surname>Tiao</surname><given-names>G.</given-names></name><name><surname>Engreitz</surname><given-names>J.M.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name></person-group><article-title>Recurrent and functional regulatory mutations in breast cancer</article-title><source>Nature</source><volume>547</volume><year>2017</year><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">28658208</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Kamel</surname><given-names>H.F.M.</given-names></name><name><surname>Al-Amodi</surname><given-names>H.S.A.B.</given-names></name></person-group><article-title>Exploitation of gene expression and cancer biomarkers in paving the path to era of personalized medicine</article-title><source>Genomics Proteomics Bioinformatics</source><volume>15</volume><year>2017</year><fpage>220</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">28813639</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>McGee</surname><given-names>S.R.</given-names></name><name><surname>Tibiche</surname><given-names>C.</given-names></name><name><surname>Trifiro</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>E.</given-names></name></person-group><article-title>Network analysis reveals a signaling regulatory loop in <italic>PIK3CA</italic>-mutated breast cancer predicting survival outcome</article-title><source>Genomics Proteomics Bioinformatics</source><volume>15</volume><year>2017</year><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">28392480</pub-id></element-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name><surname>Easton</surname><given-names>D.F.</given-names></name><name><surname>Pooley</surname><given-names>K.A.</given-names></name><name><surname>Dunning</surname><given-names>A.M.</given-names></name><name><surname>Pharoah</surname><given-names>P.D.</given-names></name><name><surname>Thompson</surname><given-names>D.</given-names></name><name><surname>Ballinger</surname><given-names>D.G.</given-names></name></person-group><article-title>Genome-wide association study identifies novel breast cancer susceptibility loci</article-title><source>Nature</source><volume>447</volume><year>2007</year><fpage>1087</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">17529967</pub-id></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>D.J.</given-names></name><name><surname>Kraft</surname><given-names>P.</given-names></name><name><surname>Jacobs</surname><given-names>K.B.</given-names></name><name><surname>Cox</surname><given-names>D.G.</given-names></name><name><surname>Yeager</surname><given-names>M.</given-names></name><name><surname>Hankinson</surname><given-names>S.E.</given-names></name></person-group><article-title>A genome-wide association study identifies alleles in <italic>FGFR2</italic> associated with risk of sporadic postmenopausal breast cancer</article-title><source>Nat Genet</source><volume>39</volume><year>2007</year><fpage>870</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">17529973</pub-id></element-citation></ref><ref id="b0240"><label>48</label><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name><surname>Haiman</surname><given-names>C.A.</given-names></name><name><surname>Chen</surname><given-names>G.K.</given-names></name><name><surname>Vachon</surname><given-names>C.M.</given-names></name><name><surname>Canzian</surname><given-names>F.</given-names></name><name><surname>Dunning</surname><given-names>A.</given-names></name><name><surname>Millikan</surname><given-names>R.C.</given-names></name></person-group><article-title>A common variant at the <italic>TERT-CLPTM1L</italic> locus is associated with estrogen receptor&#x02013;negative breast cancer</article-title><source>Nat Genet</source><volume>43</volume><year>2011</year><fpage>1210</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">22037553</pub-id></element-citation></ref><ref id="b0245"><label>49</label><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name><surname>Siddiq</surname><given-names>A.</given-names></name><name><surname>Couch</surname><given-names>F.J.</given-names></name><name><surname>Chen</surname><given-names>G.K.</given-names></name></person-group><article-title>Lindstro&#x000a8;m S, Eccles D, Millikan RC. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11</article-title><source>Hum Mol Genet</source><volume>21</volume><year>2012</year><fpage>5373</fpage><lpage>5384</lpage><pub-id pub-id-type="pmid">22976474</pub-id></element-citation></ref><ref id="b0250"><label>50</label><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name><surname>Ghoussaini</surname><given-names>M.</given-names></name><name><surname>Fletcher</surname><given-names>O.</given-names></name><name><surname>Michailidou</surname><given-names>K.</given-names></name><name><surname>Turnbull</surname><given-names>C.</given-names></name><name><surname>Schmidt</surname><given-names>M.K.</given-names></name><name><surname>Dicks</surname><given-names>E.</given-names></name></person-group><article-title>Genome-wide association analysis identifies three new breast cancer susceptibility loci</article-title><source>Nat Genet</source><volume>44</volume><year>2012</year><fpage>312</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">22267197</pub-id></element-citation></ref><ref id="b0255"><label>51</label><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Walavalkar</surname><given-names>N.M.</given-names></name><name><surname>Dozmorov</surname><given-names>M.G.</given-names></name><name><surname>Rich</surname><given-names>S.S.</given-names></name><name><surname>Civelek</surname><given-names>M.</given-names></name><name><surname>Guertin</surname><given-names>M.J.</given-names></name></person-group><article-title>Identification of breast cancer associated variants that modulate transcription factor binding</article-title><source>PLoS Genet</source><volume>13</volume><year>2017</year><fpage>e1006761</fpage><pub-id pub-id-type="pmid">28957321</pub-id></element-citation></ref><ref id="b0260"><label>52</label><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>P.</given-names></name><name><surname>Long</surname><given-names>X.</given-names></name></person-group><article-title>Differential expression profiles of the transcriptome in breast cancer cell lines revealed by next generation sequencing</article-title><source>Cell Physiol Biochem</source><volume>44</volume><year>2017</year><fpage>804</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">29176322</pub-id></element-citation></ref><ref id="b0265"><label>53</label><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name><surname>Casamassimi</surname><given-names>A.</given-names></name><name><surname>Federico</surname><given-names>A.</given-names></name><name><surname>Rienzo</surname><given-names>M.</given-names></name><name><surname>Esposito</surname><given-names>S.</given-names></name><name><surname>Ciccodicola</surname><given-names>A.</given-names></name></person-group><article-title>Transcriptome profiling in human diseases: new advances and perspectives</article-title><source>Int J Mol Sci</source><volume>18</volume><year>2017</year><fpage>1652</fpage></element-citation></ref><ref id="b0270"><label>54</label><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.G.</given-names></name><name><surname>Calin</surname><given-names>G.A.</given-names></name><name><surname>Volinia</surname><given-names>S.</given-names></name><name><surname>Croce</surname><given-names>C.M.</given-names></name></person-group><article-title>MicroRNA expression profiling using microarrays</article-title><source>Nat Protoc</source><volume>3</volume><year>2008</year><fpage>563</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">18388938</pub-id></element-citation></ref><ref id="b0275"><label>55</label><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>J.Q.</given-names></name><name><surname>Zhao</surname><given-names>R.C.</given-names></name><name><surname>Morris</surname><given-names>K.V.</given-names></name></person-group><article-title>Profiling microRNA expression with microarrays</article-title><source>Trends Biotechnol</source><volume>26</volume><year>2008</year><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">18191262</pub-id></element-citation></ref><ref id="b0280"><label>56</label><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Gelfond</surname><given-names>J.A.</given-names></name><name><surname>McManus</surname><given-names>L.M.</given-names></name><name><surname>Shireman</surname><given-names>P.K.</given-names></name></person-group><article-title>Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis</article-title><source>BMC Genomics</source><volume>10</volume><year>2009</year><fpage>407</fpage><pub-id pub-id-type="pmid">19715577</pub-id></element-citation></ref><ref id="b0285"><label>57</label><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name><surname>S&#x000f8;rlie</surname><given-names>T.</given-names></name><name><surname>Perou</surname><given-names>C.M.</given-names></name><name><surname>Tibshirani</surname><given-names>R.</given-names></name><name><surname>Aas</surname><given-names>T.</given-names></name><name><surname>Geisler</surname><given-names>S.</given-names></name><name><surname>Johnsen</surname><given-names>H.</given-names></name></person-group><article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><year>2001</year><fpage>10869</fpage><lpage>10874</lpage><pub-id pub-id-type="pmid">11553815</pub-id></element-citation></ref><ref id="b0290"><label>58</label><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Fan</surname><given-names>C.</given-names></name><name><surname>Oh</surname><given-names>D.S.</given-names></name><name><surname>Marron</surname><given-names>J.S.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Qaqish</surname><given-names>B.F.</given-names></name></person-group><article-title>The molecular portraits of breast tumors are conserved across microarray platforms</article-title><source>BMC Genomics</source><volume>7</volume><year>2006</year><fpage>96</fpage><pub-id pub-id-type="pmid">16643655</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>J.S.</given-names></name><name><surname>Mullins</surname><given-names>M.</given-names></name><name><surname>Cheang</surname><given-names>M.C.</given-names></name><name><surname>Leung</surname><given-names>S.</given-names></name><name><surname>Voduc</surname><given-names>D.</given-names></name><name><surname>Vickery</surname><given-names>T.</given-names></name></person-group><article-title>Supervised risk predictor of breast cancer based on intrinsic subtypes</article-title><source>J Clin Oncol</source><volume>27</volume><year>2009</year><fpage>1160</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">19204204</pub-id></element-citation></ref><ref id="b0300"><label>60</label><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Stern</surname><given-names>H.M.</given-names></name><name><surname>Ge</surname><given-names>L.</given-names></name><name><surname>O'Brien</surname><given-names>C.</given-names></name><name><surname>Haydu</surname><given-names>L.</given-names></name><name><surname>Honchell</surname><given-names>C.D.</given-names></name></person-group><article-title>Genetic alterations and oncogenic pathways associated with breast cancer subtypes</article-title><source>Mol Cancer Res</source><volume>7</volume><year>2009</year><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">19372580</pub-id></element-citation></ref><ref id="b0305"><label>61</label><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name><surname>Hollestelle</surname><given-names>A.</given-names></name><name><surname>Nagel</surname><given-names>J.H.</given-names></name><name><surname>Smid</surname><given-names>M.</given-names></name><name><surname>Lam</surname><given-names>S.</given-names></name><name><surname>Elstrodt</surname><given-names>F.</given-names></name><name><surname>Wasielewski</surname><given-names>M.</given-names></name></person-group><article-title>Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines</article-title><source>Breast Cancer Res Treat</source><volume>121</volume><year>2010</year><fpage>53</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19593635</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name><surname>Castaneda</surname><given-names>C.A.</given-names></name><name><surname>Andr&#x000e9;s</surname><given-names>E.</given-names></name><name><surname>Barcena</surname><given-names>C.</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>H.L.</given-names></name><name><surname>Cort&#x000e9;s-Fun&#x000e9;s</surname><given-names>H.</given-names></name><name><surname>Ciruelos</surname><given-names>E.</given-names></name></person-group><article-title>Behaviour of breast cancer molecular subtypes through tumour progression</article-title><source>Clin Transl Oncol</source><volume>14</volume><year>2012</year><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">22634538</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name><surname>Engstr&#x000f8;m</surname><given-names>M.J.</given-names></name><name><surname>Opdahl</surname><given-names>S.</given-names></name><name><surname>Hagen</surname><given-names>A.I.</given-names></name><name><surname>Romundstad</surname><given-names>P.R.</given-names></name><name><surname>Akslen</surname><given-names>L.A.</given-names></name><name><surname>Haugen</surname><given-names>O.A.</given-names></name></person-group><article-title>Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients</article-title><source>Breast Cancer Res Treat</source><volume>140</volume><year>2013</year><fpage>463</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">23901018</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name><surname>Kimbung</surname><given-names>S.</given-names></name><name><surname>Kov&#x000e1;cs</surname><given-names>A.</given-names></name><name><surname>Danielsson</surname><given-names>A.</given-names></name><name><surname>Bendahl</surname><given-names>P.O.</given-names></name><name><surname>L&#x000f6;vgren</surname><given-names>K.</given-names></name><name><surname>Stolt</surname><given-names>M.F.</given-names></name></person-group><article-title>Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>33306</fpage><lpage>33318</lpage><pub-id pub-id-type="pmid">26375671</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Xiang</surname><given-names>T.</given-names></name><name><surname>Song</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Microarray expression profiling of dysregulated long non-coding RNAs in triple-negative breast cancer</article-title><source>Cancer Biol Ther</source><volume>16</volume><year>2015</year><fpage>856</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">25996380</pub-id></element-citation></ref><ref id="b0330"><label>66</label><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name><surname>Karagoz</surname><given-names>K.</given-names></name><name><surname>Sinha</surname><given-names>R.</given-names></name><name><surname>Arga</surname><given-names>K.Y.</given-names></name></person-group><article-title>Triple negative breast cancer: a multi-omics network discovery strategy for candidate targets and driving pathways</article-title><source>OMICS</source><volume>19</volume><year>2015</year><fpage>115</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">25611337</pub-id></element-citation></ref><ref id="b0335"><label>67</label><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y.Z.</given-names></name><name><surname>Liu</surname><given-names>Y.R.</given-names></name><name><surname>Xu</surname><given-names>X.E.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>K.D.</given-names></name></person-group><article-title>Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value</article-title><source>Cancer Res</source><volume>76</volume><year>2016</year><fpage>2105</fpage><lpage>2114</lpage><pub-id pub-id-type="pmid">26921339</pub-id></element-citation></ref><ref id="b0340"><label>68</label><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.R.</given-names></name><name><surname>Jiang</surname><given-names>Y.Z.</given-names></name><name><surname>Xu</surname><given-names>X.E.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>K.D.</given-names></name><name><surname>Shao</surname><given-names>Z.M.</given-names></name></person-group><article-title>Comprehensive transcriptome profiling reveals multigene signatures in triple-negative breast cancer</article-title><source>Clin Cancer Res</source><volume>22</volume><year>2016</year><fpage>1653</fpage><lpage>1662</lpage><pub-id pub-id-type="pmid">26813360</pub-id></element-citation></ref><ref id="b0345"><label>69</label><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Xia</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name></person-group><article-title>Integrated analysis of differentially expressed genes and pathways in triple-negative breast cancer</article-title><source>Mol Med Rep</source><volume>15</volume><year>2017</year><fpage>1087</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">28075450</pub-id></element-citation></ref><ref id="b0350"><label>70</label><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Gerstein</surname><given-names>M.</given-names></name><name><surname>Snyder</surname><given-names>M.</given-names></name></person-group><article-title>RNA-Seq: a revolutionary tool for transcriptomics</article-title><source>Nat Rev Genet</source><volume>10</volume><year>2009</year><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">19015660</pub-id></element-citation></ref><ref id="b0355"><label>71</label><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>V.</given-names></name><name><surname>Angelini</surname><given-names>C.</given-names></name><name><surname>De Feis</surname><given-names>I.</given-names></name><name><surname>Ciccodicola</surname><given-names>A.</given-names></name></person-group><article-title>Uncovering the complexity of transcriptomes with RNA-Seq</article-title><source>J Biomed Biotechnol</source><volume>2010</volume><year>2010</year><fpage>853916</fpage><pub-id pub-id-type="pmid">20625424</pub-id></element-citation></ref><ref id="b0360"><label>72</label><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name><surname>Metzker</surname><given-names>M.L.</given-names></name></person-group><article-title>Sequencing technologies&#x02013;the next generation</article-title><source>Nat Rev Genet</source><volume>11</volume><year>2010</year><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">19997069</pub-id></element-citation></ref><ref id="b0365"><label>73</label><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>V.</given-names></name><name><surname>Aprile</surname><given-names>M.</given-names></name><name><surname>Esposito</surname><given-names>R.</given-names></name><name><surname>Ciccodicola</surname><given-names>A.</given-names></name></person-group><article-title>RNA-Seq and human complex diseases: recent accomplishments and future perspectives</article-title><source>Eur J Hum Genet</source><volume>21</volume><year>2013</year><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">22739340</pub-id></element-citation></ref><ref id="b0370"><label>74</label><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name><surname>van Dijk</surname><given-names>E.L.</given-names></name><name><surname>Auger</surname><given-names>H.</given-names></name><name><surname>Jaszczyszyn</surname><given-names>Y.</given-names></name><name><surname>Thermes</surname><given-names>C.</given-names></name></person-group><article-title>Ten years of next-generation sequencing technology</article-title><source>Trends Genet</source><volume>30</volume><year>2014</year><fpage>418</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">25108476</pub-id></element-citation></ref><ref id="b0375"><label>75</label><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name><surname>Edgren</surname><given-names>H.</given-names></name><name><surname>Murumagi</surname><given-names>A.</given-names></name><name><surname>Kangaspeska</surname><given-names>S.</given-names></name><name><surname>Nicorici</surname><given-names>D.</given-names></name><name><surname>Hongisto</surname><given-names>V.</given-names></name><name><surname>Kleivi</surname><given-names>K.</given-names></name></person-group><article-title>Identification of fusion genes in breast cancer by paired-end RNA-sequencing</article-title><source>Genome Biol</source><volume>12</volume><year>2011</year><fpage>R6</fpage><pub-id pub-id-type="pmid">21247443</pub-id></element-citation></ref><ref id="b0380"><label>76</label><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>K.C.</given-names></name><name><surname>Lalonde</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Cavallone</surname><given-names>L.</given-names></name><name><surname>Natrajan</surname><given-names>R.</given-names></name><name><surname>Lambros</surname><given-names>M.B.</given-names></name></person-group><article-title>Identification of gene fusion transcripts by transcriptome sequencing in <italic>BRCA1</italic>-mutated breast cancers and cell lines</article-title><source>BMC Med Genomics</source><volume>4</volume><year>2011</year><fpage>75</fpage><pub-id pub-id-type="pmid">22032724</pub-id></element-citation></ref><ref id="b0385"><label>77</label><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Ko</surname><given-names>S.</given-names></name><name><surname>In</surname><given-names>Y.H.</given-names></name><name><surname>Moon</surname><given-names>H.G.</given-names></name><name><surname>Ahn</surname><given-names>S.K.</given-names></name></person-group><article-title>Recurrent fusion transcripts detected by whole-transcriptome sequencing of 120 primary breast cancer samples</article-title><source>Genes Chromosomes Cancer</source><volume>54</volume><year>2015</year><fpage>681</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">26227178</pub-id></element-citation></ref><ref id="b0390"><label>78</label><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name><surname>Kumar-Sinha</surname><given-names>C.</given-names></name><name><surname>Kalyana-Sundaram</surname><given-names>S.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name></person-group><article-title>Landscape of gene fusions in epithelial cancers: seq and ye shall find</article-title><source>Genome Med</source><volume>7</volume><year>2015</year><fpage>129</fpage><pub-id pub-id-type="pmid">26684754</pub-id></element-citation></ref><ref id="b0395"><label>79</label><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name><surname>Veeraraghavan</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.S.</given-names></name></person-group><article-title>Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications</article-title><source>Breast Cancer Res Treat</source><volume>158</volume><year>2016</year><fpage>219</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">27372070</pub-id></element-citation></ref><ref id="b0400"><label>80</label><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name><surname>Buermans</surname><given-names>H.P.</given-names></name><name><surname>Ariyurek</surname><given-names>Y.</given-names></name><name><surname>van Ommen</surname><given-names>G.</given-names></name><name><surname>den Dunnen</surname><given-names>J.T.</given-names></name><name><surname>'t Hoen</surname><given-names>P.A.</given-names></name></person-group><article-title>New methods for next generation sequencing based microRNA expression profiling</article-title><source>BMC Genomics</source><volume>11</volume><year>2010</year><fpage>716</fpage><pub-id pub-id-type="pmid">21171994</pub-id></element-citation></ref><ref id="b0405"><label>81</label><element-citation publication-type="journal" id="h0405"><person-group person-group-type="author"><name><surname>Pritchard</surname><given-names>C.C.</given-names></name><name><surname>Cheng</surname><given-names>H.H.</given-names></name><name><surname>Tewari</surname><given-names>M.</given-names></name></person-group><article-title>MicroRNA profiling: approaches and considerations</article-title><source>Nat Rev Genet</source><volume>13</volume><year>2012</year><fpage>358</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">22510765</pub-id></element-citation></ref><ref id="b0410"><label>82</label><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>B.D.</given-names></name><name><surname>Bauer</surname><given-names>J.A.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Sanders</surname><given-names>M.E.</given-names></name><name><surname>Chakravarthy</surname><given-names>A.B.</given-names></name><name><surname>Shyr</surname><given-names>Y.</given-names></name></person-group><article-title>Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</article-title><source>J Clin Invest</source><volume>121</volume><year>2011</year><fpage>2750</fpage><lpage>2767</lpage><pub-id pub-id-type="pmid">21633166</pub-id></element-citation></ref><ref id="b0415"><label>83</label><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name><surname>Eswaran</surname><given-names>J.</given-names></name><name><surname>Cyanam</surname><given-names>D.</given-names></name><name><surname>Mudvari</surname><given-names>P.</given-names></name><name><surname>Reddy</surname><given-names>S.D.N.</given-names></name><name><surname>Pakala</surname><given-names>S.B.</given-names></name><name><surname>Nair</surname><given-names>S.S.</given-names></name></person-group><article-title>Transcriptomic landscape of breast cancers through mRNA sequencing</article-title><source>Sci Rep</source><volume>2</volume><year>2012</year><fpage>264</fpage><pub-id pub-id-type="pmid">22355776</pub-id></element-citation></ref><ref id="b0420"><label>84</label><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>V.G.</given-names></name><name><surname>Lehmann</surname><given-names>B.D.</given-names></name><name><surname>Ballinger</surname><given-names>T.J.</given-names></name><name><surname>Pietenpol</surname><given-names>J.A.</given-names></name></person-group><article-title>Subtyping of triple-negative breast cancer: implications for therapy</article-title><source>Cancer</source><volume>121</volume><year>2015</year><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">25043972</pub-id></element-citation></ref><ref id="b0425"><label>85</label><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name><surname>Le Du</surname><given-names>F.</given-names></name><name><surname>Eckhardt</surname><given-names>B.L.</given-names></name><name><surname>Lim</surname><given-names>B.</given-names></name><name><surname>Litton</surname><given-names>J.K.</given-names></name><name><surname>Moulder</surname><given-names>S.</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F.</given-names></name></person-group><article-title>Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?</article-title><source>Oncotarget</source><volume>6</volume><year>2015</year><fpage>12890</fpage><lpage>12908</lpage><pub-id pub-id-type="pmid">25973541</pub-id></element-citation></ref><ref id="b0430"><label>86</label><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name><surname>Kalimutho</surname><given-names>M.</given-names></name><name><surname>Parsons</surname><given-names>K.</given-names></name><name><surname>Mittal</surname><given-names>D.</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>J.A.</given-names></name><name><surname>Srihari</surname><given-names>S.</given-names></name><name><surname>Khanna</surname><given-names>K.K.</given-names></name></person-group><article-title>Targeted therapies for triple-negative breast cancer: combating a stubborn disease</article-title><source>Trends Pharmacol Sci</source><volume>36</volume><year>2015</year><fpage>822</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">26538316</pub-id></element-citation></ref><ref id="b0435"><label>87</label><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.R.</given-names></name><name><surname>Jiang</surname><given-names>Y.Z.</given-names></name><name><surname>Xu</surname><given-names>X.E.</given-names></name><name><surname>Yu</surname><given-names>K.D.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name></person-group><article-title>Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer</article-title><source>Breast Cancer Res</source><volume>18</volume><year>2016</year><fpage>33</fpage><pub-id pub-id-type="pmid">26975198</pub-id></element-citation></ref><ref id="b0440"><label>88</label><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name><surname>Andreopoulou</surname><given-names>E.</given-names></name><name><surname>Kelly</surname><given-names>C.M.</given-names></name><name><surname>McDaid</surname><given-names>H.M.</given-names></name></person-group><article-title>Therapeutic advances and new directions for triple-negative breast cancer</article-title><source>Breast Care (Basel)</source><volume>12</volume><year>2017</year><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">28611537</pub-id></element-citation></ref><ref id="b0445"><label>89</label><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>I.A.</given-names></name><name><surname>Abramson</surname><given-names>V.G.</given-names></name><name><surname>Lehmann</surname><given-names>B.D.</given-names></name><name><surname>Pietenpol</surname><given-names>J.A.</given-names></name></person-group><article-title>New strategies for triple-negative breast cancer-deciphering the heterogeneity</article-title><source>Clin Cancer Res</source><volume>20</volume><year>2014</year><fpage>782</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">24536073</pub-id></element-citation></ref><ref id="b0450"><label>90</label><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name><surname>McLornan</surname><given-names>D.P.</given-names></name><name><surname>List</surname><given-names>A.</given-names></name><name><surname>Mufti</surname><given-names>G.J.</given-names></name></person-group><article-title>Applying synthetic lethality for the selective targeting of cancer</article-title><source>N Engl J Med</source><volume>371</volume><year>2014</year><fpage>1725</fpage><lpage>1735</lpage><pub-id pub-id-type="pmid">25354106</pub-id></element-citation></ref><ref id="b0455"><label>91</label><element-citation publication-type="journal" id="h0455"><person-group person-group-type="author"><name><surname>Jerby-Arnon</surname><given-names>L.</given-names></name><name><surname>Pfetzer</surname><given-names>N.</given-names></name><name><surname>Waldman</surname><given-names>Y.Y.</given-names></name><name><surname>McGarry</surname><given-names>L.</given-names></name><name><surname>James</surname><given-names>D.</given-names></name><name><surname>Shanks</surname><given-names>E.</given-names></name></person-group><article-title>Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality</article-title><source>Cell</source><volume>158</volume><year>2014</year><fpage>1199</fpage><lpage>1209</lpage><pub-id pub-id-type="pmid">25171417</pub-id></element-citation></ref><ref id="b0460"><label>92</label><element-citation publication-type="journal" id="h0460"><person-group person-group-type="author"><name><surname>Rios</surname><given-names>J.</given-names></name><name><surname>Puhalla</surname><given-names>S.</given-names></name></person-group><article-title>PARP inhibitors in breast cancer: BRCA and beyond</article-title><source>Oncology (Williston Park)</source><volume>25</volume><year>2011</year><fpage>1014</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">22106552</pub-id></element-citation></ref><ref id="b0465"><label>93</label><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name><surname>Arun</surname><given-names>B.</given-names></name><name><surname>Akar</surname><given-names>U.</given-names></name><name><surname>Gutierrez-Barrera</surname><given-names>A.M.</given-names></name><name><surname>Hortobagyi</surname><given-names>G.N.</given-names></name><name><surname>Ozpolat</surname><given-names>B.</given-names></name></person-group><article-title>The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in <italic>BRCA1</italic> and <italic>BRCA2</italic> mutant breast cancer cells</article-title><source>Int J Oncol</source><volume>47</volume><year>2015</year><fpage>262</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">25975349</pub-id></element-citation></ref><ref id="b0470"><label>94</label><element-citation publication-type="journal" id="h0470"><person-group person-group-type="author"><name><surname>Livraghi</surname><given-names>L.</given-names></name><name><surname>Garber</surname><given-names>J.E.</given-names></name></person-group><article-title>PARP inhibitors in the management of breast cancer: current data and future prospects</article-title><source>BMC Med</source><volume>13</volume><year>2015</year><fpage>188</fpage><pub-id pub-id-type="pmid">26268938</pub-id></element-citation></ref><ref id="b0475"><label>95</label><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>E.R.</given-names><suffix>3rd</suffix></name><name><surname>de Weck</surname><given-names>A.</given-names></name><name><surname>Schlabach</surname><given-names>M.R.</given-names></name><name><surname>Billy</surname><given-names>E.</given-names></name><name><surname>Mavrakis</surname><given-names>K.J.</given-names></name><name><surname>Hoffman</surname><given-names>G.R.</given-names></name></person-group><article-title>Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening</article-title><source>Cell</source><volume>170</volume><year>2017</year><fpage>577</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">28753431</pub-id></element-citation></ref><ref id="b0480"><label>96</label><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>J.A.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Marshall</surname><given-names>C.B.</given-names></name><name><surname>Lehmann</surname><given-names>B.D.</given-names></name><name><surname>Pendleton</surname><given-names>C.S.</given-names></name><name><surname>Shyr</surname><given-names>Y.</given-names></name></person-group><article-title>RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells</article-title><source>Breast Cancer Res</source><volume>12</volume><year>2010</year><fpage>R41</fpage><pub-id pub-id-type="pmid">20576088</pub-id></element-citation></ref><ref id="b0485"><label>97</label><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name><surname>Kourtidis</surname><given-names>A.</given-names></name><name><surname>Jain</surname><given-names>R.</given-names></name><name><surname>Carkner</surname><given-names>R.D.</given-names></name><name><surname>Eifert</surname><given-names>C.</given-names></name><name><surname>Brosnan</surname><given-names>M.J.</given-names></name><name><surname>Conklin</surname><given-names>D.S.</given-names></name></person-group><article-title>An RNA interference screen identifies metabolic regulators <italic>NR1D1</italic> and <italic>PBP</italic> as novel survival factors for breast cancer cells with the <italic>ERBB2</italic> signature</article-title><source>Cancer Res</source><volume>70</volume><year>2010</year><fpage>1783</fpage><lpage>1792</lpage><pub-id pub-id-type="pmid">20160030</pub-id></element-citation></ref><ref id="b0490"><label>98</label><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name><surname>Boimel</surname><given-names>P.J.</given-names></name><name><surname>Cruz</surname><given-names>C.</given-names></name><name><surname>Segall</surname><given-names>J.E.</given-names></name></person-group><article-title>A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer</article-title><source>Genomics</source><volume>98</volume><year>2011</year><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">21672623</pub-id></element-citation></ref><ref id="b0495"><label>99</label><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name><surname>Marotta</surname><given-names>L.L.</given-names></name><name><surname>Almendro</surname><given-names>V.</given-names></name><name><surname>Marusyk</surname><given-names>A.</given-names></name><name><surname>Shipitsin</surname><given-names>M.</given-names></name><name><surname>Schemme</surname><given-names>J.</given-names></name><name><surname>Walker</surname><given-names>S.R.</given-names></name></person-group><article-title>The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors</article-title><source>J Clin Invest</source><volume>121</volume><year>2011</year><fpage>2723</fpage><lpage>2735</lpage><pub-id pub-id-type="pmid">21633165</pub-id></element-citation></ref><ref id="b0500"><label>100</label><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>A.P.</given-names></name><name><surname>Collier</surname><given-names>T.S.</given-names></name><name><surname>Vidavsky</surname><given-names>I.</given-names></name><name><surname>Bose</surname><given-names>R.</given-names></name></person-group><article-title>Quantitative proteomics with siRNA screening identifies novel mechanisms of Trastuzumab resistance in HER2 amplified breast cancers</article-title><source>Mol Cell Proteomics</source><volume>12</volume><year>2013</year><fpage>180</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">23105007</pub-id></element-citation></ref><ref id="b0505"><label>101</label><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name><surname>Mahmood</surname><given-names>S.F.</given-names></name><name><surname>Gruel</surname><given-names>N.</given-names></name><name><surname>Chapeaublanc</surname><given-names>E.</given-names></name><name><surname>Lescure</surname><given-names>A.</given-names></name><name><surname>Jones</surname><given-names>T.</given-names></name><name><surname>Reyal</surname><given-names>F.</given-names></name></person-group><article-title>A siRNA screen identifies <italic>RAD21</italic>, <italic>EIF3H</italic>, <italic>CHRAC1</italic> and <italic>TANC2</italic> as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation</article-title><source>Carcinogenesis</source><volume>35</volume><year>2014</year><fpage>670</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">24148822</pub-id></element-citation></ref><ref id="b0510"><label>102</label><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name><surname>Garcia-Murillas</surname><given-names>I.</given-names></name><name><surname>Sharpe</surname><given-names>R.</given-names></name><name><surname>Pearson</surname><given-names>A.</given-names></name><name><surname>Campbell</surname><given-names>J.</given-names></name><name><surname>Natrajan</surname><given-names>R.</given-names></name><name><surname>Ashworth</surname><given-names>A.</given-names></name></person-group><article-title>An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer</article-title><source>Oncogene</source><volume>33</volume><year>2014</year><fpage>2478</fpage><lpage>2486</lpage><pub-id pub-id-type="pmid">23752180</pub-id></element-citation></ref><ref id="b0515"><label>103</label><element-citation publication-type="journal" id="h0515"><person-group person-group-type="author"><name><surname>Brough</surname><given-names>R.</given-names></name><name><surname>Frankum</surname><given-names>J.R.</given-names></name><name><surname>Sims</surname><given-names>D.</given-names></name><name><surname>Mackay</surname><given-names>A.</given-names></name><name><surname>Mendes-Pereira</surname><given-names>A.M.</given-names></name><name><surname>Bajrami</surname><given-names>I.</given-names></name></person-group><article-title>Functional viability profiles of breast cancer</article-title><source>Cancer Discov</source><volume>1</volume><year>2011</year><fpage>260</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">21984977</pub-id></element-citation></ref><ref id="b0520"><label>104</label><element-citation publication-type="journal" id="h0520"><person-group person-group-type="author"><name><surname>Marcotte</surname><given-names>R.</given-names></name><name><surname>Brown</surname><given-names>K.R.</given-names></name><name><surname>Suarez</surname><given-names>F.</given-names></name><name><surname>Sayad</surname><given-names>A.</given-names></name><name><surname>Karamboulas</surname><given-names>K.</given-names></name><name><surname>Krzyzanowski</surname><given-names>P.M.</given-names></name></person-group><article-title>Essential gene profiles in breast, pancreatic, and ovarian cancer cells</article-title><source>Cancer Discov</source><volume>2</volume><year>2012</year><fpage>172</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">22585861</pub-id></element-citation></ref><ref id="b0525"><label>105</label><element-citation publication-type="journal" id="h0525"><person-group person-group-type="author"><name><surname>Giamas</surname><given-names>G.</given-names></name><name><surname>Filipovi&#x00107;</surname><given-names>A.</given-names></name><name><surname>Jacob</surname><given-names>J.</given-names></name><name><surname>Messier</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name></person-group><article-title>Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer</article-title><source>Nat Med</source><volume>17</volume><year>2011</year><fpage>715</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">21602804</pub-id></element-citation></ref><ref id="b0530"><label>106</label><element-citation publication-type="journal" id="h0530"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>K.</given-names></name><name><surname>Law</surname><given-names>J.H.</given-names></name><name><surname>Fotovati</surname><given-names>A.</given-names></name><name><surname>Dunn</surname><given-names>S.E.</given-names></name></person-group><article-title>Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells</article-title><source>Breast Cancer Res</source><volume>14</volume><year>2012</year><fpage>R22</fpage><pub-id pub-id-type="pmid">22309939</pub-id></element-citation></ref><ref id="b0535"><label>107</label><element-citation publication-type="journal" id="h0535"><person-group person-group-type="author"><name><surname>Petrocca</surname><given-names>F.</given-names></name><name><surname>Altschuler</surname><given-names>G.</given-names></name><name><surname>Tan</surname><given-names>S.M.</given-names></name><name><surname>Mendillo</surname><given-names>M.L.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name><name><surname>Jerry</surname><given-names>D.J.</given-names></name></person-group><article-title>A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells</article-title><source>Cancer Cell</source><volume>24</volume><year>2013</year><fpage>182</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">23948298</pub-id></element-citation></ref><ref id="b0540"><label>108</label><element-citation publication-type="journal" id="h0540"><person-group person-group-type="author"><name><surname>Garimella</surname><given-names>S.V.</given-names></name><name><surname>Gehlhaus</surname><given-names>K.</given-names></name><name><surname>Dine</surname><given-names>J.L.</given-names></name><name><surname>Pitt</surname><given-names>J.J.</given-names></name><name><surname>Grandin</surname><given-names>M.</given-names></name><name><surname>Chakka</surname><given-names>S.</given-names></name></person-group><article-title>Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening</article-title><source>Breast Cancer Res</source><volume>16</volume><year>2014</year><fpage>R41</fpage><pub-id pub-id-type="pmid">24745479</pub-id></element-citation></ref><ref id="b0545"><label>109</label><element-citation publication-type="journal" id="h0545"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>J.C.</given-names></name><name><surname>Chung</surname><given-names>P.E.</given-names></name><name><surname>Uehling</surname><given-names>D.</given-names></name><name><surname>Aman</surname><given-names>A.</given-names></name><name><surname>Joseph</surname><given-names>B.</given-names></name></person-group><article-title>shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer</article-title><source>Cancer Res</source><volume>74</volume><year>2014</year><fpage>2119</fpage><lpage>2130</lpage><pub-id pub-id-type="pmid">24487029</pub-id></element-citation></ref><ref id="b0550"><label>110</label><element-citation publication-type="journal" id="h0550"><person-group person-group-type="author"><name><surname>Bhola</surname><given-names>N.E.</given-names></name><name><surname>Jansen</surname><given-names>V.M.</given-names></name><name><surname>Bafna</surname><given-names>S.</given-names></name><name><surname>Giltnane</surname><given-names>J.M.</given-names></name><name><surname>Balko</surname><given-names>J.M.</given-names></name><name><surname>Estrada</surname><given-names>M.V.</given-names></name></person-group><article-title>Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer</article-title><source>Cancer Res</source><volume>75</volume><year>2015</year><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">25480943</pub-id></element-citation></ref><ref id="b0555"><label>111</label><element-citation publication-type="journal" id="h0555"><person-group person-group-type="author"><name><surname>van Roosmalen</surname><given-names>W.</given-names></name><name><surname>Le D&#x000e9;v&#x000e9;dec</surname><given-names>S.E.</given-names></name><name><surname>Golani</surname><given-names>O.</given-names></name><name><surname>Smid</surname><given-names>M.</given-names></name><name><surname>Pulyakhina</surname><given-names>I.</given-names></name><name><surname>Timmermans</surname><given-names>A.M.</given-names></name></person-group><article-title>Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant</article-title><source>J Clin Invest</source><volume>125</volume><year>2015</year><fpage>1648</fpage><lpage>1664</lpage><pub-id pub-id-type="pmid">25774502</pub-id></element-citation></ref><ref id="b0560"><label>112</label><element-citation publication-type="journal" id="h0560"><person-group person-group-type="author"><name><surname>Marcotte</surname><given-names>R.</given-names></name><name><surname>Sayad</surname><given-names>A.</given-names></name><name><surname>Brown</surname><given-names>K.R.</given-names></name><name><surname>Sanchez-Garcia</surname><given-names>F.</given-names></name><name><surname>Reimand</surname><given-names>J.</given-names></name><name><surname>Haider</surname><given-names>M.</given-names></name></person-group><article-title>Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance</article-title><source>Cell</source><volume>164</volume><year>2016</year><fpage>293</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">26771497</pub-id></element-citation></ref><ref id="b0565"><label>113</label><element-citation publication-type="journal" id="h0565"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>J.</given-names></name><name><surname>Ryan</surname><given-names>C.J.</given-names></name><name><surname>Brough</surname><given-names>R.</given-names></name><name><surname>Bajrami</surname><given-names>I.</given-names></name><name><surname>Pemberton</surname><given-names>H.N.</given-names></name><name><surname>Chong</surname><given-names>I.Y.</given-names></name></person-group><article-title>Large-scale profiling of kinase dependencies in cancer cell lines</article-title><source>Cell Rep</source><volume>14</volume><year>2016</year><fpage>2490</fpage><lpage>2501</lpage><pub-id pub-id-type="pmid">26947069</pub-id></element-citation></ref><ref id="b0570"><label>114</label><element-citation publication-type="journal" id="h0570"><person-group person-group-type="author"><name><surname>Horiuchi</surname><given-names>D.</given-names></name><name><surname>Camarda</surname><given-names>R.</given-names></name><name><surname>Zhou</surname><given-names>A.Y.</given-names></name><name><surname>Yau</surname><given-names>C.</given-names></name><name><surname>Momcilovic</surname><given-names>O.</given-names></name><name><surname>Balakrishnan</surname><given-names>S.</given-names></name></person-group><article-title>PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression</article-title><source>Nat Med</source><volume>22</volume><year>2016</year><fpage>1321</fpage><lpage>1329</lpage><pub-id pub-id-type="pmid">27775705</pub-id></element-citation></ref><ref id="b0575"><label>115</label><element-citation publication-type="journal" id="h0575"><person-group person-group-type="author"><name><surname>Workenhe</surname><given-names>S.T.</given-names></name><name><surname>Ketela</surname><given-names>T.</given-names></name><name><surname>Moffat</surname><given-names>J.</given-names></name><name><surname>Cuddington</surname><given-names>B.P.</given-names></name><name><surname>Mossman</surname><given-names>K.L.</given-names></name></person-group><article-title>Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells</article-title><source>Oncogene</source><volume>35</volume><year>2016</year><fpage>2465</fpage><lpage>2474</lpage><pub-id pub-id-type="pmid">26257065</pub-id></element-citation></ref><ref id="b0580"><label>116</label><element-citation publication-type="journal" id="h0580"><person-group person-group-type="author"><name><surname>Carninci</surname><given-names>P.</given-names></name><name><surname>Hayashizaki</surname><given-names>Y.</given-names></name></person-group><article-title>Noncoding RNA transcription beyond annotated genes</article-title><source>Curr Opin Genet Dev</source><volume>17</volume><year>2007</year><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">17317145</pub-id></element-citation></ref><ref id="b0585"><label>117</label><element-citation publication-type="journal" id="h0585"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>D.P.</given-names></name></person-group><article-title>MicroRNAs: genomics, biogenesis, mechanism, and function</article-title><source>Cell</source><volume>116</volume><year>2004</year><fpage>281</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">14744438</pub-id></element-citation></ref><ref id="b0590"><label>118</label><element-citation publication-type="journal" id="h0590"><person-group person-group-type="author"><name><surname>Nilsen</surname><given-names>T.W.</given-names></name></person-group><article-title>Mechanisms of microRNA-mediated gene regulation in animal cells</article-title><source>Trends Genet</source><volume>23</volume><year>2007</year><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">17368621</pub-id></element-citation></ref><ref id="b0595"><label>119</label><element-citation publication-type="journal" id="h0595"><person-group person-group-type="author"><name><surname>Dvinge</surname><given-names>H.</given-names></name><name><surname>Git</surname><given-names>A.</given-names></name><name><surname>Graf</surname><given-names>S.</given-names></name><name><surname>Salmon-Divon</surname><given-names>M.</given-names></name><name><surname>Curtis</surname><given-names>C.</given-names></name><name><surname>Sottoriva</surname><given-names>A.</given-names></name></person-group><article-title>The shaping and functional consequences of the microRNA landscape in breast cancer</article-title><source>Nature</source><volume>497</volume><year>2013</year><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">23644459</pub-id></element-citation></ref><ref id="b0600"><label>120</label><element-citation publication-type="journal" id="h0600"><person-group person-group-type="author"><name><surname>Riaz</surname><given-names>M.</given-names></name><name><surname>van Jaarsveld</surname><given-names>M.T.</given-names></name><name><surname>Hollestelle</surname><given-names>A.</given-names></name><name><surname>Prager-van der Smissen</surname><given-names>W.J.</given-names></name><name><surname>Heine</surname><given-names>A.A.</given-names></name><name><surname>Boersma</surname><given-names>A.W.</given-names></name></person-group><article-title>miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs</article-title><source>Breast Cancer Res</source><volume>15</volume><year>2013</year><fpage>R33</fpage><pub-id pub-id-type="pmid">23601657</pub-id></element-citation></ref><ref id="b0605"><label>121</label><element-citation publication-type="journal" id="h0605"><person-group person-group-type="author"><name><surname>Gyparaki</surname><given-names>M.T.</given-names></name><name><surname>Basdra</surname><given-names>E.K.</given-names></name><name><surname>Papavassiliou</surname><given-names>A.G.</given-names></name></person-group><article-title>MicroRNAs as regulatory elements in triple negative breast cancer</article-title><source>Cancer Lett</source><volume>354</volume><year>2014</year><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">25107641</pub-id></element-citation></ref><ref id="b0610"><label>122</label><element-citation publication-type="journal" id="h0610"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Lou</surname><given-names>F.</given-names></name></person-group><article-title>MicroRNAs-mediated cell fate in triple negative breast cancers</article-title><source>Cancer Lett</source><volume>361</volume><year>2015</year><fpage>8</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">25748387</pub-id></element-citation></ref><ref id="b0615"><label>123</label><element-citation publication-type="journal" id="h0615"><person-group person-group-type="author"><name><surname>Mathe</surname><given-names>A.</given-names></name><name><surname>Scott</surname><given-names>R.J.</given-names></name><name><surname>Avery-Kiejda</surname><given-names>K.A.</given-names></name></person-group><article-title>MiRNAs and other epigenetic changes as biomarkers in triple negative breast cancer</article-title><source>Int J Mol Sci</source><volume>16</volume><year>2015</year><fpage>28347</fpage><lpage>28376</lpage><pub-id pub-id-type="pmid">26633365</pub-id></element-citation></ref><ref id="b0620"><label>124</label><element-citation publication-type="journal" id="h0620"><person-group person-group-type="author"><name><surname>Bertoli</surname><given-names>G.</given-names></name><name><surname>Cava</surname><given-names>C.</given-names></name><name><surname>Castiglioni</surname><given-names>I.</given-names></name></person-group><article-title>MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer</article-title><source>Theranostics</source><volume>5</volume><year>2015</year><fpage>1122</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">26199650</pub-id></element-citation></ref><ref id="b0625"><label>125</label><element-citation publication-type="journal" id="h0625"><person-group person-group-type="author"><name><surname>Avery-Kiejda</surname><given-names>K.A.</given-names></name><name><surname>Braye</surname><given-names>S.G.</given-names></name><name><surname>Mathe</surname><given-names>A.</given-names></name><name><surname>Forbes</surname><given-names>J.F.</given-names></name><name><surname>Scott</surname><given-names>R.J.</given-names></name></person-group><article-title>Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer</article-title><source>BMC Cancer</source><volume>14</volume><year>2014</year><fpage>51</fpage><pub-id pub-id-type="pmid">24479446</pub-id></element-citation></ref><ref id="b0630"><label>126</label><element-citation publication-type="journal" id="h0630"><person-group person-group-type="author"><name><surname>Koduru</surname><given-names>S.V.</given-names></name><name><surname>Tiwari</surname><given-names>A.K.</given-names></name><name><surname>Leberfinger</surname><given-names>A.</given-names></name><name><surname>Hazard</surname><given-names>S.W.</given-names></name><name><surname>Kawasawa</surname><given-names>Y.I.</given-names></name><name><surname>Mahajan</surname><given-names>M.</given-names></name></person-group><article-title>A comprehensive NGS data analysis of differentially regulated miRNAs, piRNAs, lncRNAs and sn/snoRNAs in triple negative breast cancer</article-title><source>J Cancer</source><volume>8</volume><year>2017</year><fpage>578</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">28367238</pub-id></element-citation></ref><ref id="b0635"><label>127</label><element-citation publication-type="journal" id="h0635"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>A.I.</given-names></name><name><surname>Buisson</surname><given-names>M.</given-names></name><name><surname>Bertrand</surname><given-names>P.</given-names></name><name><surname>Rimokh</surname><given-names>R.</given-names></name><name><surname>Rouleau</surname><given-names>E.</given-names></name><name><surname>Lopez</surname><given-names>B.S.</given-names></name></person-group><article-title>Down-regulation of <italic>BRCA1</italic> expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers</article-title><source>EMBO Mol Med</source><volume>3</volume><year>2011</year><fpage>279</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">21472990</pub-id></element-citation></ref><ref id="b0640"><label>128</label><element-citation publication-type="journal" id="h0640"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>M.A.</given-names></name><name><surname>Sossey-Alaoui</surname><given-names>K.</given-names></name><name><surname>Thompson</surname><given-names>C.L.</given-names></name><name><surname>Danielpour</surname><given-names>D.</given-names></name><name><surname>Schiemann</surname><given-names>W.P.</given-names></name></person-group><article-title>TGF-&#x003b2; upregulates miR-181a expression to promote breast cancer metastasis</article-title><source>J Clin Invest</source><volume>123</volume><year>2013</year><fpage>150</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">23241956</pub-id></element-citation></ref><ref id="b0645"><label>129</label><element-citation publication-type="journal" id="h0645"><person-group person-group-type="author"><name><surname>Bisso</surname><given-names>A.</given-names></name><name><surname>Faleschini</surname><given-names>M.</given-names></name><name><surname>Zampa</surname><given-names>F.</given-names></name><name><surname>Capaci</surname><given-names>V.</given-names></name><name><surname>De Santa</surname><given-names>J.</given-names></name><name><surname>Santarpia</surname><given-names>L.</given-names></name></person-group><article-title>Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer</article-title><source>Cell Cycle</source><volume>12</volume><year>2013</year><fpage>1679</fpage><lpage>1687</lpage><pub-id pub-id-type="pmid">23656790</pub-id></element-citation></ref><ref id="b0650"><label>130</label><element-citation publication-type="journal" id="h0650"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>J.</given-names></name><name><surname>Berg</surname><given-names>T.</given-names></name><name><surname>Kurzejamska</surname><given-names>E.</given-names></name><name><surname>Pang</surname><given-names>M.F.</given-names></name><name><surname>Tabor</surname><given-names>V.</given-names></name><name><surname>Jansson</surname><given-names>M.</given-names></name></person-group><article-title>MiR-155-mediated loss of C/EBP&#x003b2; shifts the TGF-&#x003b2; response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer</article-title><source>Oncogene</source><volume>32</volume><year>2013</year><fpage>5614</fpage><lpage>5624</lpage><pub-id pub-id-type="pmid">23955085</pub-id></element-citation></ref><ref id="b0655"><label>131</label><element-citation publication-type="journal" id="h0655"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Richards</surname><given-names>E.J.</given-names></name><name><surname>Challa</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>C.X.</given-names></name><name><surname>Permuth-Wey</surname><given-names>J.</given-names></name></person-group><article-title>Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer</article-title><source>Oncogene</source><volume>33</volume><year>2014</year><fpage>679</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">23353819</pub-id></element-citation></ref><ref id="b0660"><label>132</label><element-citation publication-type="journal" id="h0660"><person-group person-group-type="author"><name><surname>MacKenzie</surname><given-names>T.A.</given-names></name><name><surname>Schwartz</surname><given-names>G.N.</given-names></name><name><surname>Calderone</surname><given-names>H.M.</given-names></name><name><surname>Graveel</surname><given-names>C.R.</given-names></name><name><surname>Winn</surname><given-names>M.E.</given-names></name><name><surname>Hostetter</surname><given-names>G.</given-names></name></person-group><article-title>Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer</article-title><source>Am J Pathol</source><volume>184</volume><year>2014</year><fpage>3217</fpage><lpage>3225</lpage><pub-id pub-id-type="pmid">25440114</pub-id></element-citation></ref><ref id="b0665"><label>133</label><element-citation publication-type="journal" id="h0665"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>H.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name></person-group><article-title>miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN</article-title><source>Am J Transl Res</source><volume>9</volume><year>2017</year><fpage>953</fpage><lpage>961</lpage><pub-id pub-id-type="pmid">28386324</pub-id></element-citation></ref><ref id="b0670"><label>134</label><element-citation publication-type="journal" id="h0670"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S.G.</given-names></name><name><surname>Romagnoli</surname><given-names>M.</given-names></name><name><surname>Mineva</surname><given-names>N.D.</given-names></name><name><surname>Barill&#x000e9;-Nion</surname><given-names>S.</given-names></name><name><surname>J&#x000e9;z&#x000e9;quel</surname><given-names>P.</given-names></name><name><surname>Campone</surname><given-names>M.</given-names></name></person-group><article-title>miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells</article-title><source>Breast Cancer Res</source><volume>18</volume><year>2016</year><fpage>40</fpage><pub-id pub-id-type="pmid">27039296</pub-id></element-citation></ref><ref id="b0675"><label>135</label><element-citation publication-type="journal" id="h0675"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Meng</surname><given-names>Q.</given-names></name><name><surname>Pan</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24</article-title><source>Oncotarget</source><volume>8</volume><year>2017</year><fpage>19455</fpage><lpage>19466</lpage><pub-id pub-id-type="pmid">28038450</pub-id></element-citation></ref><ref id="b0680"><label>136</label><element-citation publication-type="journal" id="h0680"><person-group person-group-type="author"><name><surname>Truong</surname><given-names>H.H.</given-names></name><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Ghotra</surname><given-names>V.P.</given-names></name><name><surname>Nirmala</surname><given-names>E.</given-names></name><name><surname>Haazen</surname><given-names>L.</given-names></name><name><surname>Le D&#x000e9;v&#x000e9;dec</surname><given-names>S.E.</given-names></name></person-group><article-title>&#x003b2;1 integrin inhibition elicits a prometastatic switch through the TGF&#x003b2;-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer</article-title><source>Sci Signal</source><volume>7</volume><year>2014</year><fpage>ra15</fpage><pub-id pub-id-type="pmid">24518294</pub-id></element-citation></ref><ref id="b0685"><label>137</label><element-citation publication-type="journal" id="h0685"><person-group person-group-type="author"><name><surname>Tsouk</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Frigo</surname><given-names>D.E.</given-names></name><name><surname>Aydo&#x0011f;du</surname><given-names>E.</given-names></name><name><surname>Williams</surname><given-names>C.</given-names></name></person-group><article-title>miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the <italic>EPHA2</italic> oncogene</article-title><source>Carcinogenesis</source><volume>36</volume><year>2015</year><fpage>1051</fpage><lpage>1060</lpage><pub-id pub-id-type="pmid">26088362</pub-id></element-citation></ref><ref id="b0690"><label>138</label><element-citation publication-type="journal" id="h0690"><person-group person-group-type="author"><name><surname>D'Ippolito</surname><given-names>E.</given-names></name><name><surname>Plantamura</surname><given-names>I.</given-names></name><name><surname>Bongiovanni</surname><given-names>L.</given-names></name><name><surname>Casalini</surname><given-names>P.</given-names></name><name><surname>Baroni</surname><given-names>S.</given-names></name><name><surname>Piovan</surname><given-names>C.</given-names></name></person-group><article-title>miR-9 and miR-200 regulate PDGFR&#x003b2;-mediated endothelial differentiation of tumor cells in triple-negative breast cancer</article-title><source>Cancer Res</source><volume>76</volume><year>2016</year><fpage>5562</fpage><lpage>5572</lpage><pub-id pub-id-type="pmid">27402080</pub-id></element-citation></ref><ref id="b0695"><label>139</label><element-citation publication-type="journal" id="h0695"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>B.D.</given-names></name><name><surname>Wali</surname><given-names>V.B.</given-names></name><name><surname>Cheng</surname><given-names>C.J.</given-names></name><name><surname>Inukai</surname><given-names>S.</given-names></name><name><surname>Booth</surname><given-names>C.J.</given-names></name><name><surname>Agarwal</surname><given-names>S.</given-names></name></person-group><article-title>miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer</article-title><source>Cancer Res</source><volume>76</volume><year>2016</year><fpage>927</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">26676753</pub-id></element-citation></ref><ref id="b0700"><label>140</label><element-citation publication-type="journal" id="h0700"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>microRNA-497 modulates breast cancer cell proliferation, invasion, and survival by targeting SMAD7</article-title><source>DNA Cell Biol</source><volume>35</volume><year>2016</year><fpage>521</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">27303812</pub-id></element-citation></ref><ref id="b0705"><label>141</label><element-citation publication-type="journal" id="h0705"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>B.</given-names></name><name><surname>Majid</surname><given-names>S.</given-names></name><name><surname>Ursu</surname><given-names>S.</given-names></name><name><surname>de Semir</surname><given-names>D.</given-names></name><name><surname>Nosrati</surname><given-names>M.</given-names></name><name><surname>Bezrookove</surname><given-names>V.</given-names></name></person-group><article-title>Tumor suppressor role of microRNA-1296 in triple-negative breast cancer</article-title><source>Oncotarget</source><volume>7</volume><year>2016</year><fpage>19519</fpage><lpage>19530</lpage><pub-id pub-id-type="pmid">26799586</pub-id></element-citation></ref><ref id="b0710"><label>142</label><element-citation publication-type="journal" id="h0710"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Zuo</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name></person-group><article-title>MicroRNA-223 increases the sensitivity of triple-negative breast cancer stem cells to trail-induced apoptosis by targeting HAX-1</article-title><source>PLoS One</source><volume>11</volume><year>2016</year><fpage>e0162754</fpage><pub-id pub-id-type="pmid">27618431</pub-id></element-citation></ref><ref id="b0715"><label>143</label><element-citation publication-type="journal" id="h0715"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.L.</given-names></name><name><surname>Zhang</surname><given-names>Z.J.</given-names></name><name><surname>Yi</surname><given-names>Z.B.</given-names></name><name><surname>Li</surname><given-names>J.J.</given-names></name></person-group><article-title>MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1</article-title><source>Br J Cancer</source><volume>117</volume><year>2017</year><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">28571042</pub-id></element-citation></ref><ref id="b0720"><label>144</label><element-citation publication-type="journal" id="h0720"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name></person-group><article-title>miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5</article-title><source>PLoS One</source><volume>12</volume><year>2017</year><fpage>e0176395</fpage><pub-id pub-id-type="pmid">28437471</pub-id></element-citation></ref><ref id="b0725"><label>145</label><element-citation publication-type="journal" id="h0725"><person-group person-group-type="author"><name><surname>Kota</surname><given-names>J.</given-names></name><name><surname>Chivukula</surname><given-names>R.R.</given-names></name><name><surname>O'Donnell</surname><given-names>K.A.</given-names></name><name><surname>Wentzel</surname><given-names>E.A.</given-names></name><name><surname>Montgomery</surname><given-names>C.L.</given-names></name><name><surname>Hwang</surname><given-names>H.W.</given-names></name></person-group><article-title>Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model</article-title><source>Cell</source><volume>137</volume><year>2009</year><fpage>1005</fpage><lpage>1017</lpage><pub-id pub-id-type="pmid">19524505</pub-id></element-citation></ref><ref id="b0730"><label>146</label><element-citation publication-type="journal" id="h0730"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>H.</given-names></name><name><surname>Fabbri</surname><given-names>M.</given-names></name><name><surname>Calin</surname><given-names>G.A.</given-names></name></person-group><article-title>MicroRNAs and other non-coding RNAs as targets for anticancer drug development</article-title><source>Nat Rev Drug Discov</source><volume>12</volume><year>2013</year><fpage>847</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">24172333</pub-id></element-citation></ref><ref id="b0735"><label>147</label><element-citation publication-type="journal" id="h0735"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Rana</surname><given-names>T.M.</given-names></name></person-group><article-title>Therapeutic targeting of microRNAs: current status and future challenges</article-title><source>Nat Rev Drug Discov</source><volume>13</volume><year>2014</year><fpage>622</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">25011539</pub-id></element-citation></ref><ref id="b0740"><label>148</label><element-citation publication-type="journal" id="h0740"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>C.J.</given-names></name><name><surname>Bahal</surname><given-names>R.</given-names></name><name><surname>Babar</surname><given-names>I.A.</given-names></name><name><surname>Pincus</surname><given-names>Z.</given-names></name><name><surname>Barrera</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name></person-group><article-title>MicroRNA silencing for cancer therapy targeted to the tumour microenvironment</article-title><source>Nature</source><volume>518</volume><year>2015</year><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">25409146</pub-id></element-citation></ref><ref id="b0745"><label>149</label><element-citation publication-type="journal" id="h0745"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Shu</surname><given-names>Y.</given-names></name><name><surname>Xiong</surname><given-names>G.</given-names></name><name><surname>Carson</surname><given-names>W.E.</given-names><suffix>3rd</suffix></name><name><surname>Haque</surname><given-names>F.</given-names></name></person-group><article-title>Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology</article-title><source>ACS Nano</source><volume>9</volume><year>2015</year><fpage>9731</fpage><lpage>9740</lpage><pub-id pub-id-type="pmid">26387848</pub-id></element-citation></ref><ref id="b0750"><label>150</label><element-citation publication-type="journal" id="h0750"><person-group person-group-type="author"><name><surname>Beavers</surname><given-names>K.R.</given-names></name><name><surname>Werfel</surname><given-names>T.A.</given-names></name><name><surname>Shen</surname><given-names>T.</given-names></name><name><surname>Kavanaugh</surname><given-names>T.E.</given-names></name><name><surname>Kilchrist</surname><given-names>K.V.</given-names></name><name><surname>Mares</surname><given-names>J.W.</given-names></name></person-group><article-title>Porous silicon and polymer nanocomposites for delivery of peptide nucleic acids as anti-microRNA therapies</article-title><source>Adv Mater</source><volume>28</volume><year>2016</year><fpage>7984</fpage><lpage>7992</lpage><pub-id pub-id-type="pmid">27383910</pub-id></element-citation></ref><ref id="b0755"><label>151</label><element-citation publication-type="journal" id="h0755"><person-group person-group-type="author"><name><surname>Rupaimoole</surname><given-names>R.</given-names></name><name><surname>Slack</surname><given-names>F.J.</given-names></name></person-group><article-title>MicroRNA therapeutics: towards a new era for the management of cancer and other diseases</article-title><source>Nat Rev Drug Discov</source><volume>16</volume><year>2017</year><fpage>203</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">28209991</pub-id></element-citation></ref><ref id="b0760"><label>152</label><element-citation publication-type="journal" id="h0760"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>S.J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Qu</surname><given-names>L.H.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>A helm model for microRNA regulation in cell fate decision and conversion</article-title><source>Sci China Life Sci</source><volume>56</volume><year>2013</year><fpage>897</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">24008388</pub-id></element-citation></ref><ref id="b0765"><label>153</label><element-citation publication-type="journal" id="h0765"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>F.</given-names></name><name><surname>Turcan</surname><given-names>S.</given-names></name><name><surname>Rimner</surname><given-names>A.</given-names></name><name><surname>Kaufman</surname><given-names>A.</given-names></name><name><surname>Giri</surname><given-names>D.</given-names></name><name><surname>Morris</surname><given-names>L.G.</given-names></name></person-group><article-title>Breast cancer methylomes establish an epigenomic foundation for metastasis</article-title><source>Sci Transl Med</source><volume>3</volume><year>2011</year><fpage>75ra25</fpage></element-citation></ref><ref id="b0770"><label>154</label><element-citation publication-type="journal" id="h0770"><person-group person-group-type="author"><name><surname>Stirzaker</surname><given-names>C.</given-names></name><name><surname>Zotenko</surname><given-names>E.</given-names></name><name><surname>Song</surname><given-names>J.Z.</given-names></name><name><surname>Qu</surname><given-names>W.</given-names></name><name><surname>Nair</surname><given-names>S.S.</given-names></name><name><surname>Locke</surname><given-names>W.J.</given-names></name></person-group><article-title>Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value</article-title><source>Nat Commun</source><volume>6</volume><year>2015</year><fpage>5899</fpage><pub-id pub-id-type="pmid">25641231</pub-id></element-citation></ref><ref id="b0775"><label>155</label><element-citation publication-type="journal" id="h0775"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>P.A.</given-names></name><name><surname>Issa</surname><given-names>J.P.</given-names></name><name><surname>Baylin</surname><given-names>S.</given-names></name></person-group><article-title>Targeting the cancer epigenome for therapy</article-title><source>Nat Rev Genet</source><volume>17</volume><year>2016</year><fpage>630</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">27629931</pub-id></element-citation></ref><ref id="b0780"><label>156</label><element-citation publication-type="journal" id="h0780"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Q.Y.</given-names></name><name><surname>Lei</surname><given-names>P.J.</given-names></name><name><surname>Zhang</surname><given-names>X.R.</given-names></name><name><surname>Zheng</surname><given-names>J.Y.</given-names></name><name><surname>Wang</surname><given-names>H.Y.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name></person-group><article-title>Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model</article-title><source>Clin Epigenetics</source><volume>8</volume><year>2016</year><fpage>34</fpage><pub-id pub-id-type="pmid">27034728</pub-id></element-citation></ref><ref id="b0785"><label>157</label><element-citation publication-type="journal" id="h0785"><person-group person-group-type="author"><name><surname>Fleischer</surname><given-names>T.</given-names></name><name><surname>Tekpli</surname><given-names>X.</given-names></name><name><surname>Mathelier</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Nebdal</surname><given-names>D.</given-names></name><name><surname>Dhakal</surname><given-names>H.P.</given-names></name></person-group><article-title>DNA methylation at enhancers identifies distinct breast cancer lineages</article-title><source>Nat Commun</source><volume>8</volume><year>2017</year><fpage>1379</fpage><pub-id pub-id-type="pmid">29123100</pub-id></element-citation></ref><ref id="b0790"><label>158</label><element-citation publication-type="journal" id="h0790"><person-group person-group-type="author"><name><surname>Geiger</surname><given-names>T.</given-names></name><name><surname>Madden</surname><given-names>S.F.</given-names></name><name><surname>Gallagher</surname><given-names>W.M.</given-names></name><name><surname>Cox</surname><given-names>J.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group><article-title>Proteomic portrait of human breast cancer progression identifies novel prognostic markers</article-title><source>Cancer Res</source><volume>72</volume><year>2012</year><fpage>2428</fpage><lpage>2439</lpage><pub-id pub-id-type="pmid">22414580</pub-id></element-citation></ref><ref id="b0795"><label>159</label><element-citation publication-type="journal" id="h0795"><person-group person-group-type="author"><name><surname>Mu&#x000f1;iz Lino</surname><given-names>M.A.</given-names></name><name><surname>Palacios-Rodr&#x000ed;guez</surname><given-names>Y.</given-names></name><name><surname>Rodr&#x000ed;guez-Cuevas</surname><given-names>S.</given-names></name><name><surname>Bautista-Pi&#x000f1;a</surname><given-names>V.</given-names></name><name><surname>Marchat</surname><given-names>L.A.</given-names></name><name><surname>Ru&#x000ed;z-Garc&#x000ed;a</surname><given-names>E.</given-names></name></person-group><article-title>Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9</article-title><source>J Proteomics</source><volume>111</volume><year>2014</year><fpage>198</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">24768906</pub-id></element-citation></ref><ref id="b0800"><label>160</label><element-citation publication-type="journal" id="h0800"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>R.T.</given-names></name><name><surname>Perez</surname><given-names>E.M.</given-names></name><name><surname>Hernandez</surname><given-names>D.</given-names></name><name><surname>Miller</surname><given-names>C.P.</given-names></name><name><surname>Haas</surname><given-names>K.M.</given-names></name><name><surname>Irie</surname><given-names>H.Y.</given-names></name></person-group><article-title>The proteomic landscape of triple-negative breast cancer</article-title><source>Cell Rep</source><volume>11</volume><year>2015</year><fpage>630</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">25892236</pub-id></element-citation></ref><ref id="b0805"><label>161</label><element-citation publication-type="journal" id="h0805"><person-group person-group-type="author"><name><surname>Tyanova</surname><given-names>S.</given-names></name><name><surname>Albrechtsen</surname><given-names>R.</given-names></name><name><surname>Kronqvist</surname><given-names>P.</given-names></name><name><surname>Cox</surname><given-names>J.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name><name><surname>Geiger</surname><given-names>T.</given-names></name></person-group><article-title>Proteomic maps of breast cancer subtypes</article-title><source>Nat Commun</source><volume>7</volume><year>2016</year><fpage>10259</fpage><pub-id pub-id-type="pmid">26725330</pub-id></element-citation></ref><ref id="b0810"><label>162</label><element-citation publication-type="journal" id="h0810"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name></person-group><article-title>Protein array-based approaches for biomarker discovery in cancer</article-title><source>Genomics Proteomics Bioinformatics</source><volume>15</volume><year>2017</year><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">28392481</pub-id></element-citation></ref><ref id="b0815"><label>163</label><element-citation publication-type="journal" id="h0815"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Recent progress in mass spectrometry proteomics for biomedical research</article-title><source>Sci China Life Sci</source><volume>60</volume><year>2017</year><fpage>1093</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">29039124</pub-id></element-citation></ref><ref id="b0820"><label>164</label><element-citation publication-type="journal" id="h0820"><person-group person-group-type="author"><name><surname>Denkert</surname><given-names>C.</given-names></name><name><surname>Bucher</surname><given-names>E.</given-names></name><name><surname>Hilvo</surname><given-names>M.</given-names></name><name><surname>Salek</surname><given-names>R.</given-names></name><name><surname>Ore&#x00161;ic</surname><given-names>M.</given-names></name><name><surname>Griffin</surname><given-names>J.</given-names></name></person-group><article-title>Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery</article-title><source>Genome Med</source><volume>4</volume><year>2012</year><fpage>37</fpage><pub-id pub-id-type="pmid">22546809</pub-id></element-citation></ref><ref id="b0825"><label>165</label><element-citation publication-type="journal" id="h0825"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>P.</given-names></name><name><surname>Ambs</surname><given-names>S.</given-names></name></person-group><article-title>Metabolic signatures of human breast cancer</article-title><source>Mol Cell Oncol</source><volume>2</volume><year>2015</year><fpage>e992217</fpage><pub-id pub-id-type="pmid">26005711</pub-id></element-citation></ref><ref id="b0830"><label>166</label><element-citation publication-type="journal" id="h0830"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Chong</surname><given-names>N.</given-names></name><name><surname>Lewis</surname><given-names>N.E.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name><name><surname>Xie</surname><given-names>G.</given-names></name><name><surname>Garmire</surname><given-names>L.X.</given-names></name></person-group><article-title>Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis</article-title><source>Genome Med</source><volume>8</volume><year>2016</year><fpage>34</fpage><pub-id pub-id-type="pmid">27036109</pub-id></element-citation></ref><ref id="b0835"><label>167</label><element-citation publication-type="journal" id="h0835"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Laird</surname><given-names>P.W.</given-names></name></person-group><article-title>Interplay between the cancer genome and epigenome</article-title><source>Cell</source><volume>153</volume><year>2013</year><fpage>38</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">23540689</pub-id></element-citation></ref><ref id="b0840"><label>168</label><element-citation publication-type="journal" id="h0840"><person-group person-group-type="author"><name><surname>Clare</surname><given-names>S.E.</given-names></name><name><surname>Shaw</surname><given-names>P.L.</given-names></name></person-group><article-title>&#x0201c;Big Data&#x0201d; for breast cancer: where to look and what you will find</article-title><source>NPJ Breast Cancer</source><volume>2</volume><year>2016</year><fpage>16031</fpage><pub-id pub-id-type="pmid">28164152</pub-id></element-citation></ref><ref id="b0845"><label>169</label><element-citation publication-type="journal" id="h0845"><person-group person-group-type="author"><name><surname>Sandhu</surname><given-names>C.</given-names></name><name><surname>Qureshi</surname><given-names>A.</given-names></name><name><surname>Emili</surname><given-names>A.</given-names></name></person-group><article-title>Panomics for precision medicine</article-title><source>Trends Mol Med</source><volume>24</volume><year>2018</year><fpage>85</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">29217119</pub-id></element-citation></ref><ref id="b0850"><label>170</label><element-citation publication-type="journal" id="h0850"><person-group person-group-type="author"><name><surname>Letai</surname><given-names>A.</given-names></name></person-group><article-title>Functional precision cancer medicine&#x02014;moving beyond pure genomics</article-title><source>Nat Med</source><volume>23</volume><year>2017</year><fpage>1028</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">28886003</pub-id></element-citation></ref><ref id="b0855"><label>171</label><element-citation publication-type="journal" id="h0855"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>E.</given-names></name><name><surname>Cho</surname><given-names>W.C.S.</given-names></name><name><surname>Wong</surname><given-names>S.C.C.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Disease biomarkers for precision medicine: challenges and future opportunities</article-title><source>Genomics Proteomics Bioinformatics</source><volume>15</volume><year>2017</year><fpage>57</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">28392478</pub-id></element-citation></ref><ref id="b0860"><label>172</label><element-citation publication-type="journal" id="h0860"><person-group person-group-type="author"><name><surname>Soysal</surname><given-names>S.D.</given-names></name><name><surname>Tzankov</surname><given-names>A.</given-names></name><name><surname>Muenst</surname><given-names>S.E.</given-names></name></person-group><article-title>Role of the tumor microenvironment in breast cancer</article-title><source>Pathobiology</source><volume>82</volume><year>2015</year><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">26330355</pub-id></element-citation></ref><ref id="b0865"><label>173</label><element-citation publication-type="journal" id="h0865"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Coming full circle&#x02014;from endless complexity to simplicity and back again</article-title><source>Cell</source><volume>157</volume><year>2014</year><fpage>267</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">24679541</pub-id></element-citation></ref><ref id="b0870"><label>174</label><element-citation publication-type="journal" id="h0870"><person-group person-group-type="author"><name><surname>Alyass</surname><given-names>A.</given-names></name><name><surname>Turcotte</surname><given-names>M.</given-names></name><name><surname>Meyre</surname><given-names>D.</given-names></name></person-group><article-title>From big data analysis to personalized medicine for all: challenges and opportunities</article-title><source>BMC Med Genomics</source><volume>8</volume><year>2015</year><fpage>33</fpage><pub-id pub-id-type="pmid">26112054</pub-id></element-citation></ref><ref id="b0875"><label>175</label><element-citation publication-type="journal" id="h0875"><person-group person-group-type="author"><name><surname>Elefsinioti</surname><given-names>A.</given-names></name><name><surname>Bellaire</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>A.</given-names></name><name><surname>Quast</surname><given-names>K.</given-names></name><name><surname>Seidel</surname><given-names>H.</given-names></name><name><surname>Braxenthaler</surname><given-names>M.</given-names></name></person-group><article-title>Key factors for successful data integration in biomarker research</article-title><source>Nat Rev Drug Discov</source><volume>15</volume><year>2016</year><fpage>369</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">27173942</pub-id></element-citation></ref><ref id="b0880"><label>176</label><element-citation publication-type="journal" id="h0880"><person-group person-group-type="author"><name><surname>McCue</surname><given-names>M.E.</given-names></name><name><surname>McCoy</surname><given-names>A.M.</given-names></name></person-group><article-title>The scope of big data in one medicine: unprecedented opportunities and challenges</article-title><source>Front Vet Sci</source><volume>4</volume><year>2017</year><fpage>194</fpage><pub-id pub-id-type="pmid">29201868</pub-id></element-citation></ref><ref id="b0885"><label>177</label><element-citation publication-type="journal" id="h0885"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Chaudhary</surname><given-names>K.</given-names></name><name><surname>Garmire</surname><given-names>L.X.</given-names></name></person-group><article-title>More is better: recent progress in multi-omics data integration methods</article-title><source>Front Genet</source><volume>8</volume><year>2017</year><fpage>84</fpage><pub-id pub-id-type="pmid">28670325</pub-id></element-citation></ref></ref-list><ack id="ak005"><title>Acknowledgments</title><p>This work was supported by the <funding-source id="gp005">National Natural Science Foundation of China</funding-source> (Grant Nos. 31230042, 31671349, and 31700712).</p></ack><fn-group><fn id="d31e256"><p id="np005">Peer review under responsibility of Beijing Institute of Genomics, Chinese Academy of Sciences and Genetics Society of China.</p></fn></fn-group></back></article>